HTG Molecular Diagnostics (HTGMQ) 10-K 25 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 15, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	0001169987
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	001-37369
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0912294
Entity Address, Address Line One	3430 E. Global Loop
Entity Address, City or Town	Tucson
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85706
City Area Code	(877)
Local Phone Number	289-2615
Document Annual Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Entity Common Stock, Shares Outstanding		6,214,400
Entity Public Float			$ 47,829,280
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 22,397,812	$ 7,619,748
Short-term investments available-for-sale, at fair value	6,298,075	25,410,222
Restricted cash		3,270,247
Accounts receivable	1,588,767	3,164,176
Inventory, net of allowance of $26,052 at December 31, 2020 and $39,403 at December 31, 2019	1,492,126	1,269,667
Prepaid expenses and other	1,094,273	633,522
Total current assets	32,871,053	41,367,582
Operating lease right-of-use assets	1,009,097	1,209,145
Property and equipment, net	1,227,402	2,240,133
Other non-current assets	90,356	302,409
Total assets	35,197,908	45,119,269
Current liabilities:
Accounts payable	1,348,762	1,662,583
Accrued liabilities	1,459,878	1,870,296
Contract liabilities - current	185,083	426,014
NuvoGen obligation - current	512,729	1,152,233
Current portion of long-term debt, net	3,022,139	2,987,667
Operating lease liabilities - current	685,220	758,932
Other current liabilities	22,563	41,134
Total current liabilities	7,236,374	8,898,859
NuvoGen obligation - non-current, net of discount	4,479,396	4,498,777
Long-term debt, net of current portion and discount and debt issuance costs	8,568,308	6,871,545
Operating lease liabilities - non-current	368,682	636,340
Other non-current liabilities	60,488	244,114
Total liabilities	20,713,248	21,149,635
Commitments and Contingencies (Note 15)
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 23,770 shares authorized, issued and outstanding at December 31, 2020 and no shares authorized, issued or outstanding at December 31, 2019	24
Common stock, $0.001 par value; 26,666,667 shares authorized at December 31, 2020 and December 31, 2019, 5,199,997 shares issued and outstanding at December 31, 2020 and 3,872,682 shares issued and outstanding at December 31, 2019	5,200	3,873
Additional paid-in-capital	205,661,999	194,288,368
Accumulated other comprehensive income (loss)	5,298	(4,964)
Accumulated deficit	(191,187,861)	(170,317,643)
Total stockholders’ equity	14,484,660	23,969,634
Total liabilities and stockholders' equity	$ 35,197,908	$ 45,119,269

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory net allowance	$ 26,052	$ 39,403
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	26,666,667	26,666,667
Common stock, shares issued	5,199,997	3,872,682
Common stock, shares outstanding	5,199,997	3,872,682
Series A Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	23,770	0
Preferred stock, shares issued	23,770	0
Preferred stock, shares outstanding	23,770	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue:
Total revenue	$ 8,548,864	$ 19,203,888
Operating expenses:
Cost of product and product-related services revenue	$ 3,991,532	$ 8,911,372
Type of Cost, Good or Service [Extensible List]	Product and Product-related Services	Product and Product-related Services
Selling, general and administrative	$ 18,063,064	$ 18,682,396
Research and development	6,079,907	10,570,225
Total operating expenses	28,134,503	38,163,993
Operating loss	(19,585,639)	(18,960,105)
Other income (expense):
Interest expense	(1,024,774)	(957,535)
Interest income	254,736	623,355
Other income	22,268
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note	(522,394)
Total other expense	(1,270,164)	(334,180)
Net loss before income taxes	(20,855,803)	(19,294,285)
Provision for income taxes	(14,415)	(3,379)
Net loss	$ (20,870,218)	$ (19,297,664)
Net loss per share, basic and diluted	$ (4.51)	$ (7.60)
Shares used in computing net loss per share, basic and diluted	4,627,918	2,539,979
Product and Product-related Services
Revenue:
Total revenue	$ 7,890,854	$ 14,632,204
Collaborative Development Services
Revenue:
Total revenue	$ 658,010	$ 4,571,684

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (20,870,218)	$ (19,297,664)
Other comprehensive income (loss), net of tax effect:
Unrealized gain on short-term investments	9	2,299
Foreign currency translation adjustment	10,253	(3,810)
Total other comprehensive income (loss)	10,262	(1,511)
Comprehensive loss	$ (20,859,956)	$ (19,299,175)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)	Total	LP Purchase Agreement	ATM Offering	Underwritten Public and Private Offerings	Private Placement	Series A Convertible Preferred Stock	Series A Convertible Preferred StockPrivate Placement	Common Stock	Common StockLP Purchase Agreement	Common StockATM Offering	Common StockUnderwritten Public and Private Offerings	Additional Paid-In Capital	Additional Paid-In CapitalLP Purchase Agreement	Additional Paid-In CapitalATM Offering	Additional Paid-In CapitalUnderwritten Public and Private Offerings	Additional Paid-In CapitalPrivate Placement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2018	$ 21,092,062							$ 1,906				$ 172,113,588					$ (3,453)	$ (151,019,979)
Balance, shares at Dec. 31, 2018								1,905,696
Exercise of stock options	120,954							$ 4				120,950
Exercise of stock options, shares								3,617
Stock-based compensation expense	1,156,486											1,156,486
Release of restricted stock awards	81							$ 5				76
Release of restricted stock awards, shares								5,431
Net share settlement of restricted stock award	(30,904)							$ (1)				(30,903)
Net share settlement of restricted stock award, shares								(1,128)
Stock issued under stock purchase plans	$ 171,190							$ 6				171,184
Stock issued under stock purchase plans, shares	500							5,830
Issuance of common stock				$ 20,758,940							$ 1,953				$ 20,756,987
Issuance of common stock, shares											1,953,236
Net loss	$ (19,297,664)																	(19,297,664)
Unrealized gain on short-term investments	2,299																2,299
Foreign currency translation adjustment	(3,810)																(3,810)
Balance at Dec. 31, 2019	23,969,634							$ 3,873				194,288,368					(4,964)	(170,317,643)
Balance, shares at Dec. 31, 2019								3,872,682
Stock-based compensation expense	1,584,666											1,584,666
Release of restricted stock awards	119							$ 8				111
Release of restricted stock awards, shares								7,911
Net share settlement of restricted stock award	(14,049)							$ (2)				(14,047)
Net share settlement of restricted stock award, shares								(1,764)
Stock issued under stock purchase plans	$ 62,162							$ 6				62,156
Stock issued under stock purchase plans, shares	0							6,286
Issuance of common stock			$ 7,545,838							$ 955				$ 7,544,883
Issuance of common stock, shares										955,240
Issuance of preferred stock	$ 2,424,900				$ 562,955	$ 41	$ 10					2,424,859				$ 562,945
Issuance of preferred stock, shares						41,100	10,170
Cancellation of common stock received in exchange for Series A convertible preferred stock	(2,424,900)							$ (274)				(2,424,626)
Cancellation of common stock received in exchange for Series A convertible preferred stock, shares								(274,000)
Conversion of Series A convertible preferred stock for common stock						$ (27)		$ 183				(156)
Conversion of Series A convertible preferred stock for common stock						(27,500)		183,333
Shares issued, including stock compensation expense		$ 1,182,083							$ 239				$ 1,181,844
Shares issued, including stock compensation expense, shares									238,658
Exercise of pre-funded warrants	31,768							$ 212				31,556
Exercise of pre-funded warrants, shares								211,784
Issuance of common stock warrants in connection with SVB Term Loan	420,000											420,000
Cash in lieu of fractional shares related to reverse stock split	(560)											(560)
Cash in lieu of fractional shares related to reverse stock split, shares								(133)
Net loss	(20,870,218)																	(20,870,218)
Unrealized gain on short-term investments	9																9
Foreign currency translation adjustment	10,253																10,253
Balance at Dec. 31, 2020	$ 14,484,660					$ 24		$ 5,200				$ 205,661,999					$ 5,298	$ (191,187,861)
Balance, shares at Dec. 31, 2020						23,770		5,199,997

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statement Of Stockholders Equity [Abstract]
At the market offering, commissions and issuance costs	$ 300,000
Private placement issuance costs	$ 37,000
Public and private offerings, underwriting discounts, commissions and issuance costs		$ 1,700,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss	$ (20,870,218)	$ (19,297,664)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,346,560	1,259,015
Accretion of discount on NuvoGen obligation	(12,936)	(13,821)
Provision for excess inventory	53,298	153,729
Write-off of Cowen ATM offering costs		108,883
Amortization of QNAH Convertible Note issuance costs	6,505	13,454
Amortization of MidCap Credit Facility discount and issuance costs	101,482	183,002
Amortization of SVB Term Loan discount and issuance costs	243,541
Stock-based compensation expense	1,584,785	1,156,567
Employee stock purchase plan expense	21,186	66,238
Non-cash operating lease expense	629,501	476,789
Accrued interest on available-for-sale securities investments	(72,503)	(325,666)
Stock compensation expense in connection with LP Purchase Agreement	205,538
Loss on extinguishment of Midcap Credit Facility and QNAH Convertible Note	522,394
Loss on abandonment and disposal of assets, net	105,063	9,051
Changes in operating assets and liabilities:
Accounts receivable	1,575,409	1,848,502
Inventory	(256,940)	(116,787)
Prepaid expenses and other	284,921	(177,307)
Deferred offering costs	140,320
Accounts payable	(23,801)	(155,974)
Accrued liabilities	(409,035)	(1,440,065)
Contract liabilities	(683,716)	188,507
Operating lease liabilities	(783,731)	(632,389)
Net cash used in operating activities	(16,292,377)	(16,695,936)
Investing activities
Purchase of property and equipment	(453,552)	(1,103,176)
Maturities of available-for-sale securities	31,650,000	32,200,000
Purchase of available-for-sale securities	(12,465,341)	(34,601,208)
Net cash provided by (used in) investing activities	18,731,107	(3,504,384)
Financing activities
Proceeds from issuance of SVB Term Loan	10,000,000
Payment of SVB Term Loan issuance costs	(115,193)
Proceeds from 2019 underwritten public and private offerings, net of underwriting discounts, commissions and costs of $1.7 million		20,758,940
Proceeds from ATM Offering, net of commissions and costs of $0.3 million	7,545,838
Proceeds from LP Purchase Agreement	976,545
Proceeds from PPP Loan	1,717,000
Proceeds from Series A convertible preferred stock in private placement	562,955
Payments on NuvoGen obligation	(645,949)	(1,327,922)
Proceeds from exercise of pre-funded warrants	31,768
Payments on financing leases	(41,134)	(44,043)
Proceeds from exercise of stock options		120,954
Taxes paid for net share settlement of restricted stock awards	(14,049)	(30,904)
Cash in Lieu of fractional shares related to reverse stock split	(560)
Proceeds from shares purchased under stock purchase plans	40,976	104,952
Payment of deferred offering costs		(190,173)
Payments on Insurance Note	(570,096)
Net cash provided by financing activities	9,049,478	19,391,804
Effect of exchange rates on cash	19,609	(4,336)
Increase (decrease) in cash, cash equivalents and restricted cash	11,507,817	(812,852)
Cash, cash equivalents and restricted cash at beginning of year	10,889,995	11,702,847
Cash, cash equivalents and restricted cash at end of year	22,397,812	10,889,995
Supplemental disclosure of noncash investing and financing activities
Issuance of Series A convertible preferred stock in exchange for outstanding common stock	2,424,900
Issuance of common stock upon conversion of Series A convertible preferred stock	1,622,500
Issuance of common stock warrants in connection with SVB Term Loan	420,000
Fixed asset purchases payable and accrued at period end		8,299
Adoption of ASC 842, Leases		694,352
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	447,987	1,005,085
Financing lease right-of-use assets obtained in exchange for financing lease liabilities		63,406
Carrying value of demonstration units transferred from property and equipment to inventory	18,817
Reclassification of contract liability to refund liability	281,722
Insurance Note issued for insurance premiums	735,195
Supplemental cash flow information
Cash paid for interest	869,857	686,042
Cash paid for taxes	17,514	$ 3,379
QNAH Convertible Note
Financing activities
Payments for extinguishment of debt	(3,000,000)
MidCap Credit Facility
Financing activities
Payments for extinguishment of debt	$ (7,438,623)

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)
2019 Underwritten Public and Private Offerings
Subsidiary Sale Of Stock [Line Items]
Underwriting discounts, commissions and issuance costs	$ 1.7
ATM Offering
Subsidiary Sale Of Stock [Line Items]
Underwriting discounts, commissions and issuance costs	$ 0.3

Description of Business, Basis

Description of Business, Basis of Presentation and Principles of Consolidation	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Description of Business, Basis of Presentation and Principles of Consolidation	Note 1. Description of Business, Basis of Presentation and Principles of Consolidation HTG Molecular Diagnostics, Inc. (the “Company”) is a provider of instruments, reagents and services for molecular profiling applications. The Company derives revenue from sales of its HTG EdgeSeq instrument system and integrated next-generation sequencing-based (“NGS-based”) HTG EdgeSeq assays, from services including sample processing and custom research use only (“RUO”) assay design and from collaborative development services. The Company operates in one segment and its customers are located primarily in the United States and Europe. For the year ended December 31, 2020, approximately 35% of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 34% for the year ended December 31, 2019. Basis of Presentation The consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In November 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen shares of issued and outstanding common stock were exchanged for one share of common stock. All share and per share amounts within the consolidated financial statements and notes thereto have been adjusted to reflect the reverse stock split for all periods and dates presented. See Note 14 for more information about the Company’s reverse stock split. Principles of Consolidation The Company formed a French subsidiary, HTG Molecular Diagnostics France SARL, in November 2018. The consolidated financial statements include the accounts of the Company and this wholly owned subsidiary after elimination of intercompany transactions and balances as of December 31, 2020 and 2019. Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations. COVID-19 Pandemic The full impact of the COVID-19 pandemic continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce. Given the ongoing evolution of the COVID-19 pandemic, including resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of the COVID-19 pandemic on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and believes that while it has seen some recovery in the later part of 2020, this impact will continue to be seen at some level at least through the first half of 2021. The extent of this impact varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. The Company has experienced very limited delays in its development efforts because of stay-at-home orders despite its efforts to prioritize the safety of its employees during this pandemic. The Company believes the COVID-19 pandemic will continue to impact its productivity, supply chains, distribution networks and other areas of its operation as ongoing concerns regarding the pandemic continue to disrupt the Company’s business and the businesses of its vendors, partners and customers and as shipping and manufacturing resources are prioritized throughout the world to fight the continued spread of the pandemic . In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID‑19 pandemic. On April 21, 2020, the Company received proceeds from a loan in the amount of $1.7 million from Silicon Valley Bank (“SVB”), as lender, pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act (the “PPP Loan”) (see Note 8). In December 2020, the Consolidated Appropriations Act (the “Appropriations Act”) was signed into law to further address the ongoing impacts of the COVID-19 pandemic. The Appropriations Act introduced several additional potential credits and benefits for employers to consider including, but not limited to, the ability for employers who have previously obtained a PPP Loan to potentially also qualify for the Employee Retention Credit, initially created as part of the CARES Act. The Company expects to qualify for benefits available to it under the Appropriations Act for the year ended December 31, 2020 and will continue to seek out these benefits in future periods as appropriate. While there remains uncertainty as to the ultimate impact of the COVID-19 pandemic, the Company has considered the known impacts on its business as of the date these consolidated financial statements were issued and has reflected any known or expected impacts in its consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position. Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of the assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $191.2 million as of December 31, 2020. As of December 31, 2020, the Company had working capital of $25.6 million and long-term liabilities of $13.5 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured Loan and Security Agreement (the “Loan Agreement”) with SVB, the PPP Loan, and a commercial financing agreement extending the payment period related to its director and officer insurance policy The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant within the Loan Agreement requiring the Company to maintain unrestricted cash of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, bonus accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory obsolescence and valuation of inventory, accounts receivable and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of the COVID-19 pandemic on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, commercial paper, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less. Accounts Receivable Accounts receivable represent valid claims against debtors. Management reviews accounts receivable regularly to determine, using the specific identification method, if any receivable amounts will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value. Investments in Available-for-Sale Securities The Company classifies its debt securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive loss, net of tax. Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense) within the consolidated statements of operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest earned on securities is also included in other income (expense) within the consolidated statements of operations. The Company recognizes other-than-temporary impairment (“OTTI”) of a debt security for which there has been a decline in fair value below amortized cost if (i) management intends to sell the security, (ii) it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, or (iii) the Company does not expect to recover the entire amortized cost basis of the security. The amount by which amortized cost exceeds the fair value of a debt security that is considered to have OTTI is separated into a component representing the credit loss, which is recognized in earnings, and a component related to all other factors, which is recognized in other comprehensive income (loss). The measurement of the credit loss component is equal to the difference between the debt security’s amortized cost basis and the present value of its expected future cash flows discounted at the security’s effective yield. If the Company intends to sell the security, or if it is more likely than not it will be required to sell the security before recovery, an OTTI write-down is recognized in earnings equal to the entire difference between the amortized cost basis and fair value of the security . Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows. December 31, 2020 2019 Cash and cash equivalents $ 22,397,812 $ 7,619,748 Restricted cash — 3,270,247 Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 22,397,812 $ 10,889,995 In October 2017, the Company received $3.0 million in gross proceeds from, and issued a subordinated convertible promissory note (the “QNAH Convertible Note”) in that principal amount to, QIAGEN North American Holdings, Inc. (“QNAH”). Amounts included in restricted cash as of December 31, 2019 represented those required to be set aside in escrow under the terms of the MidCap Credit and Security Agreement (Term Loan) (the “MidCap Term Loan”) (see Note 8) to collateralize the payment that would have been due upon maturity of the QNAH Convertible Note (see Note 8). The balance of restricted cash was released to the Company in June 2020 in conjunction with the extinguishment of the QNAH Convertible Note with proceeds from the SVB Term Loan (see Note 8). Fair Value of Financial Instruments Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The NuvoGen obligation relates to an asset purchase transaction with a then-common stockholder of the Company (see Note 10). As of December 31, 2020, the estimated aggregate fair value of the NuvoGen obligation is approximately $4.7 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. Inventory, net Inventory, consisting of raw materials, work in process and finished goods, is stated at the lower of cost (first-in, first-out) or net realizable value. Cost is determined using a standard cost system, whereby the standard costs are updated periodically to reflect current costs. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion and disposal. The Company reserves or writes down its inventory for estimated obsolescence or inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. The period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent rental agreement with the Company after evaluating the product for one year, the equipment is returned to the Company or the customer is allowed to continue use of the equipment, in which case the equipment is written off to selling, general and administrative expense in the consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation as of December 31, 2020 was $50,855 compared with $79,338 as of December 31, 2019. Property and Equipment, net Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Equipment used in the field is amortized using the straight-line method over the lesser of the period of the related reagent rental or collaborative development services agreement where applicable or the estimated useful life. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Costs incurred in the development and installation of software for internal use and in the development of the Company’s website are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount of an asset group exceeds its estimated future cash flow, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Although the Company has accumulated losses since inception, the Company believes the future cash flows will be sufficient to exceed the carrying value of the Company’s long-lived assets. There were no impairments of long-lived assets during the years ended December 31, 2020 and 2019. Leases Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheets as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For financing leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded to rent expense as incurred. Debt Issuance Costs and Debt Discounts Costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Costs incurred to issue the MidCap Credit and Security Agreement (Revolving Loan) (the “MidCap Revolving Loan”) were deferred as an asset in the consolidated balance sheets and amortized on a straight-line basis to interest expense over the term of the revolving commitment until extinguishment of the MidCap Credit and Security Agreement in June 2020 (see Note 8) . Deferred Offering Costs Deferred offering costs represent legal and other direct costs related to planned future stock offering transactions that will be charged to stockholders’ equity upon completion of the proposed stock offering. Should the proposed stock offering prove to be unsuccessful, these deferred costs, as well as any additional expenses to be incurred, will be charged to operating expense in the consolidated statements of operations. There were no deferred offering costs for the year ended December 31, 2020. Deferred offering costs of $0.1 million included as non-current assets in the consolidated balance sheet as of December 31, 2019, represented legal costs incurred by the Company in contemplation of the issuance of additional shares in a future financing transaction. In January 2020, these deferred offering costs were recorded to additional paid in capital, as an offset to proceeds received from the ATM Offering (see Note 14). Contract Liabilities Contract liabilities represent cash receipts for products or services to be delivered in future periods, including up-front fees received relating to custom RUO assay design and collaborative development services. When products or services are delivered to customers, contract liabilities are recognized as earned. Up-front fees received for custom RUO assay design or collaborative development services are recognized over time based on the costs incurred to date compared with total expected costs as design or development procedures are completed and outputs are produced. Revenue Recognition The Company accounts for its revenue in accordance with FASB, ASC 606, Revenue from Contracts with Customers Collaborative Arrangements For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company has made a policy election to exclude from the measurement of the transaction price all taxes assessed by a government authority that are both imposed on and concurrent with a specific revenue producing transaction and collected by the Company from a customer. Such taxes may include but are not limited to sales, use, value added and certain excise taxes. See Note 9 for additional discussion of the Company’s revenue recognition policies. Product Warranty The Company generally provides a one-year warranty on its HTG EdgeSeq platform covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. A provision for estimated warranty costs is recognized at the time of sale, through cost of product and product-related services revenue, based upon recent historical experience and other relevant information as it becomes available. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and adjusts the provision as needed. Warranty accrual is included in accrued liabilities in the consolidated balance sheets. Research and Development Expenses Research and development expenses represent costs incurred internally for and externally in support of research and development activities. These costs include those generated through research and development efforts for the improvement and expansion of the Company’s proprietary technology and product offerings as well as those related to third-party collaborative development agreements, for which related revenue is included in collaborative development services revenue in the consolidated statements of operations. See for further discussion of the development costs associated with collaborative development services agreements included in research and development expense in the consolidated statements of operations. Stock-based Compensation The Company incurs stock-based compensation expense relating to grants of restricted stock units (“RSUs”) and stock options to employees, consultants and non-employee directors under its equity incentive plans, and stock purchase rights granted under its Employee Stock Purchase Plan (“ESPP”). The Company recognizes expense for stock-based awards based on the fair value of awards on the date of grant. The fair value of RSUs is based on the quoted market price of the Company’s common stock on the date of grant. The fair value of ESPP rights and stock options granted pursuant to the Company’s equity incentive plans is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value utilizing the Black-Scholes option pricing model is affected by the fair value of the Company’s stock price and several assumptions, including volatility, expected term, risk-free interest rate, and dividend yield. Generally, these assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. The Company accounts for forfeitures as they occur. Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts and tax base of assets and liabilities using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established against net deferred tax assets for the uncertainty it presents of our ability to use the net deferred tax assets, in this case, primarily carryforwards of net operating tax losses and research and development tax credits. In assessing the realizability of net deferred tax assets we have assessed the likelihood that net deferred tax assets will be recovered from future taxable income, and to the extent that it is “more likely than not” that the assets will not be recovered or there is an insufficient history of operating profits, a valuation allowance is established. We record the valuation allowance in the period we determine that it is more likely than not that net deferred tax assets will not be realized. For the years ended December 31, 2020 and 2019, we have provided a full valuation allowance for all net deferred tax assets due to their current realization being considered remote in the near term. Uncertain tax positions taken or expected to be taken in a tax return are accounted for using the more likely than not threshold for financial statement recognition and measurement. Foreign Currency Translation and Foreign Currency Transactions The Company has assets and liabilities, including accounts receivable and accounts payable, which are denominated in currencies other than its functional currency. These assets and liabilities are subject to re-measurement, the impact of which is recorded in selling, general and administrative expense within the consolidated statements of operations. Adjustments resulting from translating foreign functional currency financial statements of the Company’s wholly owned subsidiary into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the consolidated statements of changes in stockholder’s equity. Comprehensive Loss Comprehensive loss includes certain changes in equity that are excluded from net loss. Specifically, unrealized gains and losses on short-term available-for-sale investments and adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in comprehensive loss. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top customer accounted for 11% of revenue for the year ended December 31, 2020, compared with the top three customers which accounted for 24%, 22% and 19% for the year ended December 31, 2019. The largest two customers accounted for approximately 9% each of the Company’s net accounts receivable as of December 31, 2020. The largest two customers accounted for approximately 29% and 25% of the Company’s net accounts receivable at December 31, 2019. Two vendors accounted for 21% and 20% of the Company’s accounts payable as of December 31, 2020 primarily related to commercial operations and inventory purchases compared with one vendor who accounted for 36% and two vendors who accounted for 10% each of the Company’s accounts payable at December 31, 2019. The Company currently relies on a single supplier to manufacture a subcomponent used in its HTG EdgeSeq instruments. A loss of this supplier could significantly delay the delivery of products, which in turn would materially affect the Company’s ability to generate revenue. Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB issued ASU No. 2018-18, which amended ASC 808, Collaborative Arrangements Recent Accounting Pronouncements The following are recent FASB ASUs that had not been adopted by the Company as of December 31, 2020: In October 2020, the FASB issued ASC Update No. 2020-10, Codification Improvements In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options Derivatives and Hedging – Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects of the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This standard is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2020. The Company does not expect the adoption of the new guidance under the standard to materially affect its financial position or results of operations. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory

Inventory	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the date indicated: December 31, 2020 2019 Raw materials $ 1,079,528 $ 872,947 Work in process 147,455 151,351 Finished goods 291,195 284,772 Total gross inventory 1,518,178 1,309,070 Less inventory allowance $ (26,052 ) $ (39,403 ) $ 1,492,126 $ 1,269,667 For the years ended December 31, 2020 and 2019, the Company recorded adjustments to the provision for excess inventory of $56,160 and $153,729, respectively. Adjustments in these periods to the allowance for estimated shrinkage, obsolescence and excess inventory have been included in cost of product and product-related services revenue in the consolidated statements of operations.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value	Note 4. Fair Value Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy, based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets measured at fair value on a recurring basis at December 31, 2020 and 2019, respectively, in the fair value hierarchy: December 31, 2020 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 17,497,282 $ — $ — $ 17,497,282 Corporate debt securities — 4,499,270 — 4,499,270 Investments available-for-sale at fair value Corporate debt securities — 6,298,075 — 6,298,075 Total $ 17,497,282 $ 10,797,345 $ — $ 28,294,627 December 31, 2019 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 7,217,096 $ — $ — $ 7,217,096 Investments available-for-sale at fair value U.S. Treasury securities 5,961,983 — — 5,961,983 Corporate debt securities — 19,448,239 — 19,448,239 Total $ 13,179,079 $ 19,448,239 $ — $ 32,627,318 There were no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the years ended December 31, 2020 and 2019. Level 1 instruments include investments in money market funds and U.S. Treasuries obligations. These instruments are valued using quoted market prices for identical unrestricted instruments in active markets. The Company defines active markets for debt instruments based on both the average daily trading volume and the number of days with trading activity. Level 2 instruments include corporate debt securities, including commercial paper. Valuations of Level 2 instruments can be verified to quoted prices, recent trading activity for identical or similar instruments, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. Consideration is given to the nature of the quotations (e.g. indicative or firm) and the relationship of recent market activity to the prices provided from alternative pricing sources. Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for either of the years ended December 31, 2020 or 2019 and did not have any Level 3 financial assets or liabilities during either of these periods.

Available-for-Sale Securities

Available-for-Sale Securities	12 Months Ended
	Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]
Available-for-Sale Securities	Note 5. Available-for-Sale Securities The Company’s portfolio of available-for-sale securities consists of high credit quality corporate debt securities as of December 31, 2020. The following is a summary of the Company’s available-for-sale securities at December 31, 2020 and 2019: December 31, 2020 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 6,298,075 — — 6,298,075 Total available-for-sale securities $ 6,298,075 $ — $ — $ 6,298,075 December 31, 2019 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 5,962,224 $ 394 $ (635 ) $ 5,961,983 Corporate debt securities 19,448,239 — - 19,448,239 Total available-for-sale securities $ 25,410,463 $ 394 $ (635 ) $ 25,410,222 There were no gross unrealized losses relating to the Company’s available-for-sale securities investments as of December 31, 2020. The net adjustment to unrealized holding gains on short-term investments, net of tax in other comprehensive income totaled $9 and $2,299 for the years ended December 31, 2020 and 2019, respectively. Contractual maturities of debt investment securities at December 31, 2020 are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total Corporate debt securities 6,298,075 — 6,298,075 Total available-for-sale securities $ 6,298,075 $ — $ 6,298,075 For debt securities, the Company determines whether it intends to sell or if it is more likely than not that it will be required to sell impaired securities. This determination considers current and forecasted liquidity requirements, regulatory and capital requirements and securities portfolio management. For all impaired debt securities for which there was no intent or expected requirement to sell, the evaluation considers all available evidence to assess whether it is likely the amortized cost value will be recovered. The Company conducts a regular assessment of its debt securities with unrealized losses to determine whether securities have other-than-temporary impairment considering, among other factors, the nature of the securities, credit rating or financial condition of the issuer, the extent and duration of the unrealized loss, expected cash flows of underlying collateral, market conditions and whether the Company intends to sell or it is more likely than not that the Company will be required to sell the debt securities. As the Company did not have any unrealized losses as of December 31, 2020, there were no other-than-temporary impairments of its available-for-sale securities.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net consists of the following as of the dates indicated: December 31, 2020 2019 Furniture & fixtures $ 1,082,717 $ 1,089,371 Leasehold improvements 1,943,534 1,987,997 Equipment used in manufacturing 2,166,743 2,305,340 Equipment used in research & development 2,506,644 2,134,019 Equipment used in the field 208,005 182,762 Software 420,301 374,812 Property and equipment 8,327,944 8,074,301 Less: accumulated depreciation and amortization (7,100,542 ) (5,834,168 ) $ 1,227,402 $ 2,240,133 Depreciation and leasehold improvement amortization expense was $1.3 million for both of the years ended December 31, 2020 and 2019.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consist of the following as of the dates indicated: December 31, 2020 2019 Accrued employee bonuses $ 436,799 $ 900,740 Payroll and employee benefit accruals 694,058 469,530 Accrued interest 61,676 245,350 Other accrued liabilities 267,345 254,676 $ 1,459,878 $ 1,870,296

Debt Obligations

Debt Obligations	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations. Current portion of long-term debt, net, consists of the following as of the dates indicated: December 31, 2020 2019 Convertible note, net of debt issuance costs $ — $ 2,987,667 SVB Term Loan payable 2,000,000 — PPP Loan 857,040 — Insurance Note Payable 165,099 — $ 3,022,139 $ 2,987,667 Long-term debt, net of current portion and discount and debt issuance costs, consisted of the following as of the dates indicated: December 31, 2020 2019 MidCap Term Loan payable, net of discount and debt issuance costs $ — $ 6,871,545 SVB Term Loan payable, net of discount and debt issuance costs 7,708,348 — PPP Loan 859,960 — $ 8,568,308 $ 6,871,545 MidCap Credit Facility On March 26, 2018 (the “MidCap Closing Date”), the Company entered into the MidCap Term Loan and MidCap Revolving Loan (together the “MidCap Credit Facility”) with MidCap Financial Trust, as agent. MidCap Financial Trust subsequently assigned its rights and obligations as agent to MidCap Funding IV Trust. The MidCap Term Loan provided a secured term loan facility in an aggregate principal amount of up to $20.0 million. The Company borrowed the first advance of $7.0 million (“MidCap Tranche 1”) on the MidCap Closing Date, which was used to repay in full all outstanding amounts and fees due under the Company’s previous Loan and Security Agreement with a syndicate of two lending institutions, Oxford Finance LLC and SVB, as well as for ongoing working capital and general corporate purposes. MidCap Tranche 1 bore interest at a floating rate equal to 7.25% per annum, plus the greater of (i) 1.25% or (ii) the one-month LIBOR. In February 2020, the MidCap Credit Facility was amended to, amongst other things, extend the interest-only payments on the term loan advances by an additional 11 months, with principal on each term loan advance payable in 25 equal monthly installments beginning March 1, 2021 until paid in full on March 1, 2023. The amendment also provided that if the Company achieved a stated revenue milestone for the 12-month period ending December 31, 2020, the interest-only period would be further extended by an additional four months, with principal on MidCap Tranche 1 then payable in 21 equal monthly installments beginning July 1, 2021. This amendment was accounted for as a modification for accounting purposes. The MidCap Term Loan also required that the Company deliver subordination documents with respect to the QNAH Convertible Note, or that the QNAH Convertible Note otherwise be converted or prepaid, on or before June 30, 2018, and required the Company to deposit $3.3 million into an escrow account by July 15, 2018 if neither event occurred by such date. As neither event occurred prior to June 30, 2018, the Company deposited $3.3 million into an escrow account on July 11, 2018. The escrowed funds were released to the Company on June 25, 2020 in conjunction with the extinguishment of the QNAH Convertible Note with proceeds from the SVB Term Loan (see below). Unamortized debt discount associated with the MidCap Term Loan of $443,455, resulting from fees and debt issuance costs, was recognized in the consolidated balance sheets as of December 31, 2019. Unamortized costs incurred in connection with the issuance of the Midcap Revolving Loan of $50,970 Amortization of the debt discount associated with the MidCap Term Loan was $93,719 and $166,904 for the years ended December 31, 2020 and 2019, respectively, and was included in interest expense in the consolidated statements of operations. Amortization of deferred MidCap Revolving Loan costs was $7,763 and $16,098 for the years ended December 31, 2020 and 2019, respectively, and is included in interest expense in the consolidated statements of operations. QNAH Convertible Note In October 2017, the Company issued a subordinated convertible promissory note to QNAH in the principal amount of $3.0 million against receipt of cash proceeds equal to such principal amount. The QNAH Convertible Note incurred simple interest at the rate of 3.0% per annum and matured on October 26, 2020. On June 25, 2020, in connection with the closing of the SVB Term Loan, the Company repaid in full the QNAH Convertible Note and accrued interest in the aggregate amount of $3.2 million. Extinguishment of MidCap Credit Facility and QNAH Convertible Note upon SVB Term Loan Closing On June 25, 2020, the Company repaid all principal and interest amounts outstanding under the MidCap Credit Facility in an aggregate amount equal to $7.5 million, including collateral agent legal fees and prepayment fees. The repayment was funded with net proceeds from the SVB Term Loan (see description of the SVB Term Loan below). As a result of the repayment, the Company recorded a loss on extinguishment of the MidCap Credit Facility and the QNAH Convertible Note of $0.5 million, including remaining unamortized discounts of $0.3 million and prepayment and other MidCap Credit Facility and QNAH Convertible Note lender fees and issuance costs in other expense in the consolidated statements of operations for the year ended December 31, 2020. All obligations under the MidCap Credit Facility and the QNAH Convertible Note were fulfilled upon extinguishment of the MidCap Credit Facility. SVB Term Loan On June 24, 2020 (the “Closing Date”), the Company entered into a Loan and Security Agreement, by and among the Company and SVB, as lender, which provides a secured term loan in the principal amount of $10.0 million (the “SVB Term Loan”). The proceeds from the SVB Term Loan were fully funded on the June 25, 2020. The SVB Term Loan bears interest at a floating rate equal to the greater of 2.50% above the Prime Rate (as defined in the Loan Agreement) and 5.75%. Interest on the SVB Term Loan is due and payable monthly in arrears. The SVB Term Loan has interest-only payments through June 30, 2021. The interest only period may be extended for six months upon the achievement of an equity milestone as fully defined in the Loan Agreement. The ultimate interest-only period will be followed by equal monthly payments of principal and interest through the maturity date of December 1, 2023. Prepayments of the SVB Term Loan, in whole or in part, will be subject to early termination fees in an amount equal to 3.0% of principal prepaid if prepayment occurs on or prior to the first anniversary of the Closing Date, 2.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date but on or prior to the second anniversary of the Closing Date, and 1.0% of principal prepaid if prepayment occurs after the second anniversary of the Closing Date and prior to the maturity date. Upon termination of the Loan Agreement, the Company is required to pay a final fee equal to 8.00% of the principal amount of the SVB Term Loan. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge). Additionally, the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the Loan Agreement. The Loan Agreement contains customary affirmative covenants and customary negative covenants limiting the Company’s ability and the ability of the Company’s subsidiaries, if any, to, among other things, dispose of assets, undergo a change in control, merge or consolidate, make acquisitions, incur debt, incur liens, pay dividends, repurchase stock and make investments, in each case subject to certain exceptions. The Company must also comply with a financial covenant requiring the Company to maintain unrestricted cash at an account with SVB of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. While the Company is required to maintain this minimum cash balance, it is not legally restricted by the agreement from withdrawing funds. The Loan Agreement also contains customary events of default relating to, among other things, payment defaults, breaches of covenants, a material adverse change, delisting of the Company’s common stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments, and inaccuracies of representations and warranties. Upon an event of default, SVB may declare all or a portion of the Company’s outstanding obligations to be immediately due and payable and exercise other rights and remedies provided for under the agreement. During the existence of an event of default, interest on the obligations could be increased by 5.0%. In connection with the Loan Agreement, the Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The fair value of the warrant on the date of issuance was $0.4 million, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the SVB Term Loan, with a corresponding credit to additional paid in capital since the warrant met the requirements to be classified in equity. The Company included $1.1 million of debt discount associated with the SVB Term Loan, resulting from fees and debt issuance costs, inclusive of the fair value of warrants issued, in long-term debt, net in the as of December 31, 2020. Amortization of the debt discount associated with the SVB Term Loan was $0.2 million for the year ended December 31, 2020 and was included in interest expense in the . The effective interest rate for the year ended December 31, 2020 was 11.11%. The remaining principal repayments due under the SVB Term Loan as of December 31, 2020 are as follows for each fiscal year: 2021 $ 2,000,000 2022 4,000,000 2023 4,000,000 Total SVB Term Loan payments 10,000,000 Less discount and deferred financing costs (1,091,652 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 9,708,348 Paycheck Protection Program Loan On April 21, 2020, the Company received proceeds from a loan in the amount of $1.7 million from SVB, as lender, pursuant to the Paycheck Protection Program of the CARES Act. The PPP Loan is evidenced by a promissory note (the “Note”), which contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the PPP Loan documents. The PPP Loan matures on April 21, 2022 and bears interest at an annual rate of 1%. Beginning on September 21, 2021, the Company is required to make eight equal monthly payments of principal and interest. The PPP Loan may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from the PPP Loan may only be used for payroll costs (including benefits), rent and utility obligations, and interest on certain of the Company’s other debt obligations. All or a portion of the PPP Loan may be forgiven by the U.S. Small Business Administration (“SBA”) upon application and documentation by the Company of expenditures in accordance with the SBA requirements. Under the CARES Act and PPP Flexibility Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the 24-week period beginning on the date of loan approval. For purposes of the PPP, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 40% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if a Company’s full-time headcount declines, or if salaries and wages for employees with salaries of $100,000 or less annually are reduced by more than 25% during the measurement period, unless certain safe harbors are satisfied. In the event the PPP Loan, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal and interest. The Company applied for full PPP Loan forgiveness in October 2020. However, there can be no assurance given that the Company will obtain forgiveness of the PPP Loan in whole or in part. In order to apply for the PPP Loan, the Company certified that, among other things, the current economic uncertainty made the PPP Loan request necessary to support its ongoing operations. In addition, PPP loans under the CARES Act may be subject to certain rules, regulations and Standard Operating Procedures (“SOPs”) applicable to the SBA’s Section 7(a) Loan Program, which includes PPP loans under the CARES Act. The interpretation and applicability of these rules, regulations and SOPs is unclear, as some of them have not been referenced in the CARES Act itself or in the guidance and interpretations issued by the SBA to date. If it is determined that the Company was not eligible to receive the PPP Loan, or that the Company has not adequately complied with the rules, regulations and SOPs applicable to the SBA’s Section 7(a) Loan Program, the Company could be subject to penalties and could be required to repay the PPP Loan in its entirety. Insurance Note On April 27, 2020, the Company entered into the Insurance Note to extend the payment period related to its director and officer insurance policy. The Insurance Note required a down payment to be made upon signing the agreement equal to $0.2 million. The unpaid premium balance of $0.7 million was financed at an annual rate of 3.61%. The Insurance Note is being repaid in nine equal monthly payments of principal and interest beginning on June 6, 2020. The Insurance Note contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the Insurance Note documents. The Insurance Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	Note 9. Revenue from Contracts with Customers Revenue from contracts with customers is recognized when, or as, the Company satisfies its performance obligations by delivering the promised goods or service deliverables to the customers. A good or service deliverable is transferred to a customer when, or as, the customer obtains control of that good or service deliverable. A performance obligation may be satisfied over time or at a point in time. Revenue from a performance obligation satisfied over time is recognized by measuring the Company’s progress in satisfying the performance obligation in a manner that depicts the transfer of the goods or services to the customer. Revenue from a performance obligation satisfied at a point in time is recognized at the point in time that the Company determines the customer obtains control over the promised good or service deliverable. The amount of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services ( i.e. Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the years ended December 31, 2020 and 2019 as follows: Years Ended December 31, 2020 2019 Product revenue: Instrument $ 869,035 $ 1,436,730 Consumables 3,030,612 3,010,094 Total product revenue 3,899,647 4,446,824 Product-related services revenue: Custom RUO assay design 1,393,316 4,498,088 RUO sample processing 2,597,891 5,687,292 Total product-related services revenue 3,991,207 10,185,380 Total product and product-related services revenue $ 7,890,854 $ 14,632,204 Because the Company’s agreements for product and product-related services revenue have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Sale of instruments and consumables The delivery of each instrument and related installation and calibration are considered to be a single performance obligation, as the HTG EdgeSeq instrument must be professionally installed and calibrated prior to use. Instrument product revenue is generally recognized upon installation and calibration of the instrument by field service engineers, which represents the point at which the customer has the ability to use the instrument and has accepted the asset. Installation generally occurs within one month of instrument shipment. The delivery of each consumable is a separate performance obligation. Consumables revenue is recognized upon transfer of control, which represents the point when the customer has legal title and the significant risks of ownership of the asset. The Company’s standard terms and conditions provide that no right of return exists for instruments and consumables, unless replacement is necessary due to delivery of defective or damaged product. Customer payment terms vary but are typically between 30 and 90 days of revenue being earned from shipment or delivery, as applicable. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the consolidated statements of operations as part of product and product-related services revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included in the consolidated statements of operations as part of cost of product and product-related services For sales of consumables in the United States, standard delivery terms are FOB shipping point, unless otherwise specified in the customer contract, reflecting transfer of control to the customer upon shipment. Standard delivery terms for sales to customers outside of the United States are FOB delivery point, unless otherwise specified in the customer contract. The Company has elected the practical expedient to account for shipping and handling as activities to fulfill the promise to transfer the consumables. The Company provides instruments to certain customers under reagent rental agreements. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances, the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. The Company measures progress toward complete satisfaction of its performance obligation to provide the instrument and deliver the consumables using an output method based on the number of consumables delivered in relation to the total consumables to be provided under the reagent rental agreement. This is considered to be representative of the delivery of outputs under the arrangement and the best measure of progress because the customer benefits from the instrument only in conjunction with the consumables. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. The cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase, in which case the instrument would be expensed as cost of product and product-related services Service Revenue RUO Sample Processing The Company also provides sample preparation and processing services and molecular profiling of retrospective cohorts for its customers through its VERI/O laboratory, whereby the customer provides samples to be processed using HTG EdgeSeq technology specified in the order. Customers are charged a per sample fee for sample processing services which is recognized as revenue upon delivery of a data file to the customer showing the results of testing and completing delivery of the agreed upon service. This is when the customer can use and benefit from the results of testing and the Company has the present right to payment. Custom RUO Assay Design and Related Agreements The Company enters into custom RUO assay design agreements that may generate up-front fees and subsequent payments that might be earned upon completion of design process phases. The Company measures progress toward complete satisfaction of its performance obligation to perform custom RUO assay design using an output method based on the costs incurred to date compared with total expected costs, as this is representative of the delivery of outputs under the arrangements and the best measure of progress. However, because in most instances the assay development fees are contingent upon completion of each phase of the design project and the decision of the customer to proceed to the next phase, the amount to be included in the transaction price and recognized as revenue is limited to that which the customer is contractually obligated to pay upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company did not recognize any custom RUO assay design revenue from performance obligations that were satisfied in previous periods during the year ended December 31, 2020 compared with $41,137 for the year ended December 31, 2019. Collaborative Development Services Revenue The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. Collaborative development services revenue related to these contracts for the years ended December 31, 2020 and 2019 was generated through statements of work entered into under the Governing Agreement with QIAGEN Manchester Limited (“QML”) as discussed below. Years Ended December 31, 2020 2019 Collaborative development services $ 658,010 $ 4,571,684 Master Assay Development, Commercialization and Manufacturing Agreement In November 2016, the Company entered into a Master Assay Development, Commercialization and Manufacturing Agreement with QML (the “Governing Agreement”). The Company has determined that SOW Two and SOW Three are collaborative arrangements and that QML meets the definition of a customer under ASC 606. Additionally, each SOW is a separate contract with a single performance obligation to provide development services. Under each SOW, QML pays the Company a monthly fee for development work performed by the Company and its subcontractors (collectively, the “Monthly Fee”). The Monthly Fee is based on the employee and materials costs incurred during the month, which is subject to significant variability from period to period and unknown until the costs are incurred. Therefore, the Monthly Fee, which is based on use of hours and costs as a measure of progress, is included in the transaction price and recognized as revenue over time when the costs are incurred, and the Monthly Fee is billed to QML. It is at this time that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company and QML also share any net profits resulting from performance of the development work as determined pursuant to the Governing Agreement. Such profit-sharing payment(s) are deemed to be variable consideration using the expected value method and are included in the transaction price upon completion of the respective SOW deliverables, acceptance of corresponding deliverables, and the mutual agreement by QML and the Company on the calculation of net profit, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Because each SOW has an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations for each SOW. Statement of Work No. Two In October 2017, the Company and QML entered into the second statement of work under the Governing Agreement (“SOW Two”), which was made effective as of June 2, 2017 (“Onset Date”). The Company and QML amended SOW Two twice in August 2018 and two additional times in September 2018 and February 2019. The initial-phase investigational-use-only (“IUO”) development activities under SOW Two and the first three amendments related to next phases, which included the use of the IUO assay developed in the initial-phase in a retrospective clinical trial and in additional disease indications were completed prior to 2020. Development activities agreed upon in the fourth amendment of SOW Two were completed in the fourth quarter of 2020. As of December 31, 2020, there are no additional agreed upon development activities to be completed under SOW Two. Revenue of $0.7 million, inclusive of SOW Two Monthly Fees and $0.2 million of SOW Two profit-sharing payments has been included in collaborative development services revenue in the consolidated statements of operations for the year ended December 31, 2020. Revenue of $2.7 million, inclusive of SOW Two Monthly Fees and $0.7 million of SOW Two profit-sharing payments has been included in collaborative development services revenue in the consolidated statements of operations for the year ended December 31, 2019. Accounts receivable relating to SOW Two of $0.1 million and $0.2 million remained in the consolidated balance sheets as of December 31, 2020 and 2019, respectively. Costs relating to development activities conducted by the Company pursuant to SOW Two of $0.5 million have been included in research and development expense in the consolidated statements of operations for the year ended December 31, 2020, compared with $1.8 million for the year ended December 31, 2019. Statement of Work No. Three In January 2018, the Company and QML entered into a third statement of work under the Governing Agreement (“SOW Three”) and amended SOW Three in September 2018. Initial assay development activities under SOW Three were completed prior to 2020 and development procedures contemplated in the first amendment to SOW Three have remained on hold throughout 2020, pending customer decision as to whether to proceed with next phase contract activities. There was no revenue recognized, or development costs incurred relating to SOW Three for the year ended December 31, 2020. Revenue of $1.9 million, inclusive of SOW Three Monthly Fees and $0.7 million of SOW Three profit-sharing payments has been included in collaborative development services revenue in the consolidated statements of operations for the year ended December 31, 2019. Accounts receivable relating to SOW Three of $0.8 million remained in the consolidated balance sheets as of December 31, 2019. Costs relating to development activities conducted by the Company pursuant to SOW Three of $1.0 million have been included in research and development expense in the consolidated statements of operations for the year ended December 31, 2019. Contract Liabilities The Company receives up-front payments from customers for custom RUO assay design and sample processing services. In addition, payments for instrument extended warranty contracts are required to be made in advance. The Company recognizes such up-front payments as contract liabilities. The contract liabilities are subsequently reduced at the point in time that the data files are delivered for sample processing services or as the Company satisfies its performance obligations over time for RUO assay design and extended warranty services. Contract liabilities of $0.2 million and $0.6 million were included in contract liabilities – current and other non-current liabilities in the consolidated balance sheets as of December 31, 2020 and 2019, respectively. Changes in the Company’s contract liabilities were as follows as of the dates indicated: Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2020 $ 95,148 $ 66,216 $ 438,090 $ 599,454 Deferral of revenue 500,045 566,733 124,404 1,191,182 Recognition of deferred revenue (491,613 ) (632,949 ) (186,888 ) (1,311,450 ) Transfer to refund liability — — (281,722 ) (281,722 ) Balance at December 31, 2020 $ 103,580 $ — $ 93,884 $ 197,464 Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2019 $ 116,547 $ 50,000 $ 244,400 $ 410,947 Deferral of revenue 218,802 972,267 529,913 1,720,982 Recognition of deferred revenue (240,201 ) (956,051 ) (336,223 ) (1,532,475 ) Balance at December 31, 2019 $ 95,148 $ 66,216 $ 438,090 $ 599,454

Other Agreements

Other Agreements	12 Months Ended
	Dec. 31, 2020
Other Agreements [Abstract]
Other Agreements	Note 10. Other Agreements NuvoGen Obligation The Company entered into an asset purchase agreement in 2001, as amended, with NuvoGen Research, LLC (“NuvoGen”) to acquire certain intellectual property from NuvoGen. The Company accounted for the transaction as an asset acquisition. However, as the intellectual property was determined to not have an alternative future use, the upfront consideration was expensed. In exchange for the intellectual property, the Company agreed to pay total aggregate cash compensation to NuvoGen under the agreement of $15.0 million. Certain terms of the agreement were amended in November 2003, September 2004, November 2012 and February 2014. Pursuant to the latest amendment to the agreement, the Company is obligated to pay the greater of $0.4 million or 6% of annual revenue until the obligation is paid in full. The Company paid yearly fixed fees, in quarterly installments, to NuvoGen of $0.4 million as well as revenue-based payments of $0.2 million and $0.9 million during the years ended December 31, 2020 and 2019, respectively, for the amount by which 6% of revenue exceeded the applicable fixed fee. Beginning on January 1, 2019 and continuing until the remaining obligation has been paid in full, interest on the remaining unpaid obligation is being accrued and will compound annually at a rate of 2.5% per year. Accrued interest related to this obligation is payable on the date that the remaining obligation is paid in full. Minimum payments to be made in 2021 include $54,777 of revenue-based payments payable as of December 31, 2020 and an estimate of additional revenue-based payments to be made throughout the remainder of 2021 relating to revenue generated in the first, second and third quarters of 2021 using actual revenue generated in the same quarters in 2020. Minimum payments for the remaining years include only the minimum payments for each year. Actual payments could be significantly more than provided in the table, to the extent that 6% of the Company’s annual revenue in those years exceeds $0.4 million: 2021 $ 512,729 2022 400,000 2023 400,000 2024 400,000 2025 400,000 2025 and beyond 2,800,021 Total NuvoGen obligation payments 4,912,750 Plus interest accretion 79,376 Total NuvoGen obligation, net $ 4,992,126 The Company has recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, which represents the Company’s estimate of its effective borrowing rate for similar obligations. The unamortized interest accretion was $(79,376) and $(92,311) at December 31, 2020 and 2019, respectively. Discount accreted during the years ended December 31, 2020 and 2019 was $(12,935), and $(13,821), respectively.

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	Note 11. Leases Operating Leases T he Company leases office space and equipment under agreements classified as operating leases that expire on various dates through 2023. The Company’s most significant active leases as of December 31, 2020 are for office and manufacturing space in Tucson, Arizona and a development laboratory space in San Carlos, California. The Company amended its Tucson facility leases in December 2020 to extend the terms for one year, through January 31, 2022. The lease extension, treated as a lease modification for accounting purposes, allows for an additional extension of three years upon the same terms and conditions of the existing amended lease agreements, except that the lease rates would be adjusted to reflect lease rates applicable to like-kind buildings within the market at the time that the Company elects to exercise the extension option, but in no event less than the last applicable rental rate. The Company’s leases do not include any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Certain of the Company’s leases include renewal options and escalation clauses. Renewal options have not been included in the calculation of the Company’s lease liabilities and right-of-use assets as of December 31, 2020, as the Company is not reasonably certain to exercise the options. Annual rent increases are included in the calculation of the operating lease right-of-use assets. Variable expenses generally represent the Company’s share of the landlord’s operating expenses and are recorded when incurred. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to the rates for similar length secured lines of credit to the Company’s lease agreements provided by the Company’s lenders at the time that the lease liabilities were recorded, as these rates represented the cost of borrowing for secured loans of similar duration. The Company does not have any operating lease arrangements where it acts as a lessor. The components of lease cost for operating leases were as follows: Years Ended December 31, 2020 2019 Operating leases Operating lease cost $ 752,413 $ 618,463 Variable lease cost 125,792 131,387 Operating lease expense 878,205 749,850 Short-term lease rent expense — 1,497 Total rent expense $ 878,205 $ 751,347 The table below summarizes other information related to the Company’s operating leases: Years Ended December 31, 2020 2019 Cash paid for amounts included in measurement of operating lease liabilities $ 883,252 $ 770,658 Establishment of operating lease liabilities arising from obtaining right-of-use assets $ 515,409 $ 2,038,193 Weighted-average remaining lease term – operating leases 1.7 2.3 Weighted-average discount rate – operating leases 8.0 % 9.6 % As of December 31, 2020, remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows: 2021 $ 746,724 2022 319,678 2023 70,848 Total 1,137,250 Less present value discount (83,348 ) Total operating lease liabilities 1,053,902 Less operating lease liabilities - current (685,220 ) Non-current operating lease liabilities - non-current $ 368,682 Financing Leases The Company has a number of computer and copier equipment leases that are classified as financing leases. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to information received by the Company from bankers regarding estimated current borrowing rates for collateralized loans with similar amount and duration as the leases. Years Ended December 31, 2020 2019 Financing leases Amortization of right-of-use assets $ 42,826 $ 46,255 Interest on lease liability 8,938 6,859 Total financing lease cost $ 51,764 $ 53,114 The table below summarizes other information related to the Company’s financing leases: Years Ended December 31, 2020 2019 Weighted-average remaining lease term – financing leases 3.4 3.7 Weighted-average discount rate – financing leases 9.77 % 9.77 % As of December 31, 2020, remaining maturities of the Company’s financing leases are as follows: 2021 $ 28,355 2022 20,716 2023 18,396 2024 16,080 Total 83,547 Less present value discount (12,873 ) Financing lease liabilities, net $ 70,674 As of December 31, 2020, the Company had financing lease liabilities net of discount of $70,674, of which $22,563 was included in other current liabilities and $48,111 was included in other non-current liabilities, and financing right-of-use assets of $66,770, which were included in property and equipment, net, in the consolidated balance sheets.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Net Loss per Share	Note 12. Net Loss Per Share Basic loss per common share is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. In September 2019, in connection with the Securities Purchase Agreement (see Note 14), the Company issued and sold pre-funded warrants exercisable for an aggregate of 360,779 shares of common stock. The total exercise price of the pre-funded warrants is $9.75 per share, $9.60 of which was pre-funded and paid to the Company upon issuance of the pre-funded warrants. The remaining exercise price of the pre-funded warrants is $0.15 per share. The pre-funded warrants are exercisable by the holders at any time and do not expire. In March 2020, prefunded warrants representing 211,784 shares of the Company’s common stock were exercised for proceeds of $31,768. The remaining pre-funded warrants are immediately exercisable and do not expire. As the remaining shares underlying the pre-funded warrants are issuable for nominal consideration of $0.15 per share, 148,995 in common shares underlying the unexercised pre-funded warrants were considered outstanding for purposes of the calculation of loss per share as of December 31, 2020. In connection with the SVB Term Loan (see Note 8), the Company granted SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or, at the election of the holder, on a cashless, net exercise basis. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Years Ended December 31, 2020 2019 Numerator: Net loss $ (20,870,218 ) $ (19,297,664 ) Denominator: Weighted-average shares outstanding-basic and diluted * 4,627,918 2,539,979 Net loss per share, basic and diluted $ (4.51 ) $ (7.60 ) *Reflects the retrospective adjustment related to the reverse stock split completed on November 20, 2020. The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Years Ended December 31, 2020 2019 Options to purchase common stock 487,227 193,660 Series A Preferred 158,545 — Common stock warrants 58,689 15,794 Restricted stock units 12,214 14,916 QNAH convertible note — 53,357

Warrants

Warrants	12 Months Ended
	Dec. 31, 2020
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 13. Warrants In connection with certain of its redeemable convertible preferred stock issuances, debt agreements, convertible debt and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock which have since been converted to common stock warrants. In connection with the Securities Purchase Agreement (see Note 14), the Company issued and sold pre-funded warrants exercisable for an aggregate of 360,779 shares of common stock. The total exercise price of the pre-funded warrants is $9.75 per share, $9.60 of which was pre-funded and paid to the Company upon issuance of the pre-funded warrants. The remaining exercise price of the pre-funded warrants is $0.15 per share. The pre-funded warrants are exercisable by the holders at any time and do not expire. In March 2020, prefunded warrants representing 211,784 shares of the Company’s common stock were exercised for proceeds of $31,768. As of December 31, 2020, pre-funded warrants to purchase an aggregate of 148,995 shares of the Company’s common stock were outstanding. In connection with the SVB Term Loan (see Note 8), the Company granted SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or, at the election of the holder, on a cashless, net exercise basis. The following table shows the common stock warrants outstanding as of December 31, 2020: Warrant Issuance Date Shares of Common Underlying Warrants Exercise Price/Share Expiration Date August 2014 1,914 $ 352.65 2024 December 2014 9,651 210.00 2022 March 2016 3,021 41.40 2026 March 2018 1,208 115.95 2028 September 2019 148,995 0.15 N/A June 2020 42,894 11.6565 2030

Stockholders Equity

Stockholders Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	Public and Private Offerings 2019 Underwritten Public and Private Offerings Public Offering In September 2019, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (“Cantor”), relating to the issuance and sale in a public offering of 1,953,236 shares of its common stock, including 254,770 shares sold pursuant to the full exercise of the underwriter’s option to purchase additional shares. The price to the public in the offering was $9.75 per share and the underwriter agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $9.165 per share. The net proceeds to the Company were $17.7 million, after deducting the underwriting discounts and commissions and offering expenses. The offering was made pursuant to the Company’s registration statement on Form S-3 (Registration Statement No. 333‑229045), previously filed with the Securities and Exchange Commission (“SEC”) and declared effective by the SEC on February 11, 2019, and a prospectus supplement and accompanying prospectus thereunder. Securities Purchase Agreement In September 2019, concurrent with the closing of the September 2019 underwritten public offering, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers, in a private placement transaction, warrants to purchase up to an aggregate of 360,779 shares of its common stock (“Warrant Shares”), at a price of $9.60 per warrant (which $9.60 price relates to the pre-funded portion of the total $9.75 exercise price per share). Each pre-funded warrant has a remaining exercise price of $0.15 per share and became immediately exercisable upon issuance, subject to certain beneficial ownership limitations. The exercise price of the pre-funded warrants will be subject to adjustment in the event of any stock dividends and splits, recapitalization, reorganization or similar transaction, as described in the pre-funded warrants. The pre-funded warrants are exercisable on a “cashless” basis in certain circumstances. Cantor (the “Placement Agent”) acted as the sole placement agent in connection with the private placement of the warrants. Pursuant to a Placement Agency Agreement between the Company and the Placement Agent, the Company agreed to pay the Placement Agent a cash fee equal to 6% of the gross proceeds from the sale of the pre-funded warrants, and to provide reimbursement for certain out-of-pocket expenses. Upon closing, the Company received $3.1 million in net proceeds from the sale of the pre-funded warrants in the private placement, which does not include proceeds that may be received upon exercise of the pre-funded warrants, after deducting the Placement Agent fee and other expenses. In March 2020, 211,784 of the pre-funded warrants were exercised for additional proceeds of $31,768. ATM Offering In November 2019, the Company entered into a Controlled Equity Offering Sales Agreement (the “Cantor Sales Agreement”) with Cantor as sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.001 per share, having an aggregate offering price of up to $20.0 million, by any method deemed to be an “at the market offering” as defined by rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-229045). Approximately $81,000 of costs incurred in connection with the offering were capitalized as deferred offering costs in the Company’s consolidated balance sheets upon entry into this agreement in addition to the Form S-3 costs capitalized under a previous ATM offering that was never activated of which $45,000 were reimbursable by Cantor through reduction of commissions earned on shares sold under the Cantor Sales Agreement. The Company is not obligated to sell any shares under the Cantor Sales Agreement and pays Cantor a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, has reimbursed legal fees and disbursements and has provided Cantor with customary indemnification and contribution rights. The Cantor Sales Agreement may be terminated by Cantor or the Company at any time upon notice to the other party, or by Cantor at any time in certain circumstances, including the occurrence of a material and adverse change in the Company’s business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. During the year ended December 31, 2020, the Company sold 955,240 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of $7.9 million. After deferred offering costs included as non-current assets in the consolidated balance sheets as of December 31, 2019 of $0.1 million and paying sales commissions owned in connection with the ATM Offering of $0.2 million, the Company’s aggregate net proceeds for the year ended December 31, 2020 were $7.5 million. There were no shares sold under the Cantor Sales Agreement through December 31, 2019. See Note 17 for further information regarding the ATM Offering. Exchange and Private Placement On February 25, 2020, the Company entered into an Exchange and Purchase Agreement (the “Exchange Agreement”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to (i) issue to the Investors an aggregate of 41,100 shares of its newly designated Series A Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred”), in exchange for the Investors surrendering to the Company for cancellation an aggregate of 274,000 shares of its common stock (the “Exchange”) and (ii) sell and issue to the Investors an aggregate of 10,170 shares of Series A Preferred for an aggregate purchase price of $0.6 million, or $59.00 per share (the “Private Placement”), both of which were completed prior to the end of February 2020. In February 2020, in connection with the Exchange Agreement and the planned issuance of shares of Series A Preferred pursuant to the Exchange and Private Placement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Series A Certificate of Designation”). The Series A Certificate of Designation establishes and designates the Series A Preferred and the rights, preferences and privileges thereof. Each share of Series A Preferred is convertible into 6.67 shares of the Company’s common stock, subject to proportional adjustment and beneficial ownership limitations. In June 2020, certain of the Investors elected to convert 27,500 shares of Series A Preferred to common stock in the aggregate, resulting in the issuance of 183,333 shares of the Company’s common stock. The remaining 23,770 Series A Preferred shares remain outstanding as of December 31, 2020. In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred will participate pari passu with any distribution of proceeds to holders of the Company’s common stock. Holders of Series A Preferred are entitled to receive dividends on shares of Series A Preferred equal (on an as converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock. Shares of Series A Preferred generally have no voting rights, except as required by law. LP Purchase Agreement On March 24, 2020, the Company entered into a purchase agreement ("LP Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right to sell to Lincoln Park up to $20.0 million of shares of its common stock (“Purchase Shares”) from time to time over the 36-month term of the LP Purchase Agreement. The Company may sell up to 20,000 shares of its common stock to Lincoln Park in a regular purchase on any single business day that the closing price of its stock is not below $1.50. The minimum purchase amount per day must be equal to or greater than $150,000 to the extent the Company chooses to sell shares to Lincoln Park. This amount may be increased to up to 23,333 shares if the closing price of the Company’s common stock is not below $7.50 and to up to 26,666 shares if the closing price of the Company’s common stock is not below $11.25. In each case, the maximum amount of any single business day’s Purchase Shares may be increased up to 166,666 shares. The Company may direct Lincoln Park to purchase shares as often as every business day subject to the limitations outlined above. For each sale of common stock during the period of the agreement, the purchase price of the Purchase Shares will be established by a formula based on the recent closing prices of the Company’s common stock leading up to the date of sale. In addition to the regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases if the closing sales price of the Company’s common stock exceeds certain threshold prices as set forth in the LP Purchase Agreement. Under applicable rules of The Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the LP Purchase Agreement shares of its common stock in excess of 19.99% of the shares of the Company’s common stock outstanding immediately prior to execution of the LP Purchase Agreement (the “Exchange Cap”), unless (i) the Company obtains stockholder approval to issue shares of its common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of its common stock to Lincoln Park under the LP Purchase Agreement equals or exceeds $5.2155, such that issuances and sales of the common stock to Lincoln Park under the purchase agreement would be exempt from the issuance limitation under applicable Nasdaq rules. The Company determined that the right to sell additional shares represents a freestanding put option under derivative accounting guidance, but has a fair value of zero, and therefore no additional accounting was required. Lincoln Park has no right to require the Company to sell any shares of its common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as directed by the Company, subject to the limitations outlined above. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the LP Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than 9.99% of the Company’s common stock. The Company issued Lincoln Park an aggregate of 41,026 shares of its common stock as consideration for their purchase commitment pursuant to the LP Purchase Agreement. During the year ended December 31, 2020, the Company sold 197,632 shares of common stock under the LP Purchase Agreement at a weighted average price of $4.94 per share for total gross proceeds of $1.0 million. Additional sales of shares of common stock to Lincoln Park under the LP Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, trading price of the Company’s common stock and determinations by the Company as to the appropriate sources of funding for the Company. Common Stock On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen (15) shares of issued and outstanding common stock were exchanged for one share of its common stock. No fractional shares were issued in the reverse stock split. Instead, fractional shares that would have otherwise resulted from the stock split were purchased by us at the applicable percentage of $4.27 per share. All share and per share amounts included within these financial statements have been retrospectively adjusted to reflect the reverse stock split. Pursuant to its amended and restated certificate of incorporation, the Company is authorized to issue 26,666,667 shares of common stock at a par value of $0.001 per share. Each share of common stock is entitled to one vote. The shares of common stock have no preemptive or conversion rights, no redemption or sinking fund provisions, no liability for further call or assessment, and are not entitled to cumulative voting rights. Preferred Stock Pursuant to its amended and restated certificate of incorporation, the Company has been authorized to issue 10,000,000 shares of preferred stock, each having a par value of $0.001. The preferred stock may be issued from time to time in one or more series with the authorization of the Company’s Board of Directors. The Board of Directors can determine voting power for each series issued, as well as designation, preferences, and relative, participating, optional or other rights and such qualifications, limitations or restrictions thereof. Stock-based Compensation The Company incurs stock-based compensation expense relating to the grants of RSUs and stock options to employees, non-employee directors and consultants under its equity incentive plans and through stock purchase rights granted under the ESPP. Equity Incentive Plans The Company initially established the 2001 Stock Option Plan (the “2001 Plan”), which included incentive and nonqualified stock options and restricted stock to be granted to directors, officers, employees, consultants and others. The 2001 Plan terminated, and no further awards were granted under the 2001 Plan upon the effective date of the Company’s 2011 Equity Incentive Plan (the “2011 Plan”). In May 2015, the 2011 Plan terminated, and no further awards were granted under the 2011 plan upon the effective date of the Company’s 2014 Equity Incentive Plan (the “2014 Plan”). There were no shares of the Company’s stock available for issuance under the 2014 Plan as of December 31, 2019, other than those reserved for inducement awards, as outlined below. On January 1, 2020, an additional 154,907 shares were registered for issuance under the 2014 Plan pursuant to an evergreen provision contained in the 2014 Plan. In May 2019, 13,333 shares were reserved for issuance under the 2014 Plan pursuant to an amendment approved by the Company’s Board of Directors pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules, to be used exclusively for the grant of awards to individuals who were not previously employees or non-employee directors of the Company, as inducement material to the individuals’ entering into employment with the Company (“Inducement Awards”). In August 2020, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the 2020 Equity Incentive Plan (the “2020 Plan”) as a successor to and continuation of the 2014 Plan. Upon approval of the 2020 Plan, 744,685 shares, including 68,552 remaining shares reserved for issuance under the 2014 Plan (excluding shares available for the granting of Inducement Awards under the 2014 Plan’s inducement share pool), were reserved for issuance under the 2020 Plan. No new awards may be granted under the 2014 Plan. There were 513,619 shares of the Company’s common stock available for issuance under the 2020 Plan as of December 31, 2020 in addition to shares that may become available from time to time as shares of our common stock subject to outstanding awards granted under the 2014 Plan (excluding Inducement Awards), the 2011 Plan or the 2001 Plan that, following the effective date of the 2020 Plan (i) are not issued because such award or any portion thereof expires or otherwise terminates without all of the shares covered by such award having been issued; (ii) are not issued because such award or any portion thereof is settled in cash; or (iii) are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. The 2020 Plan does not contain an evergreen provision. The Company’s Board of Directors determines the grant date for all awards granted under the 2020 Plan. The exercise price of stock options granted is generally equal to the closing price of the Company’s common stock on the date of grant or on the employee’s hire date for new hire grants. All stock options granted have a ten-year term. The vesting period of stock options and RSUs is established by the Company’s Board of Directors but typically ranges between one and four years. Amounts recognized in the consolidated statements of operations with respect to the Company’s equity incentive plans were as follows: Years Ended December 31, 2020 2019 Selling, general and administrative $ 1,461,190 $ 859,653 Research and development 106,267 243,804 Cost of product and product-related services revenue 17,328 53,110 $ 1,584,785 $ 1,156,567 The following table summarizes stock option activity during the two-year period ended December 31, 2020: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at January 1, 2019 136,482 $ 46.05 7.6 $ 366,007 Granted 84,667 22.20 Exercised (3,617 ) 33.45 $ 21,380 Forfeited (10,771 ) 49.35 Expired/Cancelled (13,101 ) 48.45 Balance at December 31, 2019 193,660 $ 35.55 8.0 $ 781 Granted 387,178 7.81 Exercised - - $ - Forfeited (67,369 ) 12.99 Expired/Cancelled (26,242 ) 32.04 Balance at December 31, 2020 487,227 $ 16.78 8.6 $ 1,536 Exercisable at December 31, 2019 92,058 42.60 6.6 $ 1,440 Exercisable at December 31, 2020 187,031 27.07 7.5 $ 305 The weighted-average fair value of stock options granted was $6.40 and $14.55 for the years ended December 31, 2020 and 2019, respectively. The 2019 stock option activity includes 5,333 Inducement Awards granted during the year ended December 31, 2019 compared with no Inducement Awards granted during the year ended December 31, 2020. As of December 31, 2020, total unrecognized compensation cost related to stock option awards was approximately $2.3 million, which is expected to be recognized over approximately 2.29 years. The fair value of each stock option granted has been determined using the Black-Scholes option pricing model. The material factors incorporated in the Black-Scholes model in estimating the fair value of the stock options granted for the periods presented were as follows: 2020 2019 Fair value of common stock on grant date $4.35 - 11.25 $10.20 - 33.90 Risk-free interest rate 0.34% - 1.65% 1.43% - 2.21% Expected volatility 109.1% - 149.9% 63.9% - 97.1% Expected term 5.4 to 5.9 years 5.5 to 6.1 years Expected dividend yield 0% 0% • Expected stock price volatility • Risk-free interest rate • Expected term • Expected dividend yield In preparing its Black-Scholes option-pricing model fair value calculations, the Company does not estimate a forfeiture rate to calculate stock-based compensation. The Company uses judgment in evaluating the expected volatility and expected terms utilized for the Company’s stock-based compensation calculations on a prospective basis. The following table summarizes RSU award activity during the two-year period ended December 31, 2020: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at January 1, 2019 15,180 $ 49.50 Granted 5,167 28.95 Released (5,431 ) 49.65 Balance at December 31, 2019 14,916 $ 43.65 Granted 7,000 7.83 Released (7,911 ) 35.85 Forfeited (1,791 ) 41.23 Balance at December 31, 2020 12,214 $ 28.61 Vested and unissued at December 31, 2020 1,390 $ 33.21 The weighted-average fair value of RSUs granted was $7.83 and $28.95 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, total unrecognized compensation cost related to RSU awards was approximately $0.3 million, which is expected to be recognized over approximately 1.69 years. Vested and unissued awards at December 31, 2020 represents RSU awards granted in August 2018, January 2019, September 2019 and August 2020 for which a portion of the awards vested on December 31, 2020, but for which issuance of shares occurred in January 2021. 2014 Employee Stock Purchase Plan In April 2015, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan, which became effective in May 2015. The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, from January 1, 2016 to January 1, 2024 by the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 13,000 shares, or (iii) a number determined by the Company’s Board of Directors that is less than (i) and (ii). The ESPP enables participants to contribute up to 15% of such participant’s eligible compensation during a defined period (not to exceed 27 months) to purchase common stock of the Company. The purchase price of common stock under the ESPP is the lesser of: (i) 85% of the fair market value of a share of the Company’s common stock on the first day of an offering or (ii) 85% of the fair market value of the Company’s common stock at the applicable purchase date. Amounts recognized in the consolidated statements of operations with respect to the ESPP were as follows: Years Ended December 31, 2020 2019 Selling, general and administrative $ 12,106 $ 43,615 Research and development 5,248 18,454 Cost of product and product-related services revenue 3,832 4,169 $ 21,186 $ 66,238 During the year ended December 31, 2020, employees entering the plan at various times throughout the offering period purchased the following shares at the end of each of the ESPP’s six-month purchase periods: June 2020 December 2020 Number of Shares Price per Share Number of Shares Price per Share ESPP Group: Group A 3,033 $ 8.29 2,857 $ 4.87 Group B - N/A 396 4.87 Total number of shares purchased 3,033 3,253 During the year ended December 31, 2019, employees entering the plan at various times throughout the offering period purchased the following shares at the end of each of the ESPP’s six-month purchase periods: June 2019 December 2019 Number of Shares Price per Share Number of Shares Price per Share ESPP Group: Group A 1,972 $ 23.59 1,830 $ 8.55 Group B 389 26.78 349 8.55 Group C 305 26.78 320 8.55 Group D - N/A 165 8.55 Total number of shares purchased 2,666 2,664 As of December 31, 2020, approximately 24,922 shares of the Company’s common stock were reserved for future issuance under the ESPP. On January 1, 2021, an additional 13,000 shares were registered for issuance pursuant to an evergreen provision contained in the ESPP. The Company recognizes ESPP expense based on the fair value of the ESPP stock purchase rights, estimated for each six-month purchase period using the Black-Scholes option pricing model. The model requires the Company to make subjective assumptions, including expected stock price volatility, risk free rate of return and estimated life. The fair value of equity-based awards is amortized straight-line over the vesting period of the award. The material factors incorporated in the Black-Scholes model in estimating the fair value of the ESPP awards for the periods presented were as follows: 2020 2019 Fair value of common stock $8.70 - 9.75 $27.75 - 60.00 Risk-free interest rate 0.18% - 1.58% 1.88% - 2.37% Expected volatility 65.8% - 88.9% 79.5% - 85.8% Expected term 0.5 years 0.5 years Expected dividend yield 0% 0% • Fair value of common stock • Expected stock price volatility • Risk-free interest rate • Expected term • Expected dividend yield Stock Purchase Plan In December 2015, the Board of Directors adopted a Stock Purchase Plan (the “Purchase Plan”) which allows directors, any individual deemed by the Board of Directors to be an officer for purposes of Section 16 of the Exchange Act, and anyone designated by the Board of Directors as eligible to participate in the Purchase Plan to purchase shares of the Company’s common stock from the Company at fair market value. The aggregate number of shares of common stock that may be issued under the Purchase Plan shall not exceed 16,666 shares of common stock, and a maximum of 500 shares of common stock may be purchased by any one participant on any one purchase date. The Board of Directors or an authorized committee must review and approve each individual request to purchase common stock under the Purchase Plan. No stock was sold under the Purchase Plan during the year ended December 31, 2020. Cash received from the sale of common stock by the Company to eligible participants for the year ended December 31, 2019 was $17,250, which resulted in the sale of 500 shares of the Company’s common stock at fair market value. As of December 31, 2020, there were 11,658 shares available for issuance under the Purchase Plan.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Employee Agreements The Company has entered into Severance and Change in Control Plan agreements with certain named executive officers and various other members of management, which provide salary continuation payments, bonuses and, in certain instances, the acceleration of the vesting of certain equity awards to individuals in the event that the individual is terminated other than for cause, as defined in the applicable agreement. Indemnification Agreements In the course of operating its business, the Company has entered into, and continues to enter into, separate indemnification agreements with the Company’s directors and executive officers, in addition to the indemnification provided for in the Company’s amended and restated bylaws. These agreements may require the Company to indemnify its directors and executive officers for certain expenses incurred in any action or proceeding arising out of their services as one of the Company’s directors or executive officers. Product Warranty The following is a summary of the Company’s general product warranty liability, which is included in accrued liabilities in the consolidated balance sheets for the years ended December 31, 2020 and 2019: Years Ended December 31, 2020 2019 Beginning balance $ 94,482 $ 63,461 Cost of warranty claims (32,866 ) (40,055 ) Increase in warranty reserve 31,080 71,076 Ending balance $ 92,696 $ 94,482 Defined Contribution Plan In January 2003, the Company established a defined contribution plan (“401(k) Plan”) under section 401(k) of the Internal Revenue Code of 1986, as amended (the “IRC”). All employees who are over the age of 21 and who are expected to work at least 1,000 hours in a calendar year are eligible for participation in the 401(k) Plan upon commencement of employment with the Company. The Company may make discretionary contributions to the 401(k) Plan but has not done so during the years ended December 31, 2020 and 2019.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 16. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as the realization of the net deferred tax assets is uncertain. As a result, the Company has not recorded any federal or state income tax benefit in the accompanying consolidated statements of operations; however, income tax expense has been recorded for state minimum and foreign income taxes. The Company periodically reviews its filing positions for all open tax years in all U.S. federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is “more likely than not” that the position will be sustained on audit, including resolution of related appeals or litigation process, if any. The term “more likely than not” means a likelihood of more than 50 percent. If the tax position is not more likely than not to be sustained in a court of last resort, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the more likely than not criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. As discussed below, the Company has estimated $3.0 million and $2.7 million of uncertain tax positions as of December 31, 2020 and 2019, respectively, related to certain tax credit carryforwards. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at December 31, 2020 or 2019, and has not recognized interest or penalties during the years ended December 31, 2020 and 2019, since there was no reduction in income taxes paid due to uncertain tax positions. Management of the Company believes no significant change to the amount of unrecognized tax benefits will occur within the next 12 months. The following table summarizes loss before income taxes: Years Ended December 31, 2020 2019 U.S. pre-tax loss $ (20,855,184 ) $ (19,332,809 ) Foreign pre-tax gain (loss) (619 ) 38,524 Loss before income taxes $ (20,855,803 ) $ (19,294,285 ) The components of income tax expense are as follows: Years Ended December 31, 2020 2019 Current: Federal $ — $ — State 10,860 3,379 Foreign 3,555 — Total current income tax expense $ 14,415 $ 3,379 Deferred: Federal $ — $ — State — — Foreign — — Total deferred income tax expense $ — $ — Total income tax expense $ 14,415 $ 3,379 The Company’s actual income tax expense for the years ended December 31, 2020 and 2019 differ from the expected amount computed by applying the statutory federal income tax rate to loss before income taxes as follows: Years Ended December 31, 2020 2019 Computed tax (benefit) at 21% $ (4,379,719 ) $ (4,051,800 ) State taxes, net of federal benefit (832,055 ) (881,670 ) Stock-based compensation 310,811 183,167 Foreign tax rate differential 3,685 4,298 Return to provision 26,120 80,668 Other 31,850 51,737 Research and development tax credit - state (218,991 ) (342,320 ) Research and development tax credit - federal (197,836 ) (301,878 ) Uncertain tax position adjustment for prior periods (5,694 ) 650,687 Increase in valuation allowance 5,276,244 4,610,490 $ 14,415 $ 3,379 Deferred tax assets and liabilities comprise the following: Years Ended December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 43,308,483 $ 38,357,970 Research and development credits 3,475,341 3,061,981 Deferred revenue 50,429 154,497 Inventory reserve 6,653 10,155 Fixed assets and intangibles 313,117 217,332 Accrued NuvoGen liability 1,274,896 1,456,435 Lease liability 269,147 359,603 Other 211,574 150,134 Gross deferred tax assets 48,909,640 43,768,107 Valuation allowance (48,626,925 ) (43,350,682 ) Deferred tax assets, net 282,715 417,425 Deferred tax liabilities: Right of use asset 257,705 311,633 Other 25,010 105,792 Total deferred tax liabilities 282,715 417,425 Net deferred tax assets (liabilities) $ - $ - As of December 31, 2020, the Company has estimated federal and state net operating loss (“NOL”) carryforwards of approximately $177.6 million and $124.5 million for federal and state income tax purposes, respectively, of which $121.8 million are scheduled to expire from 2021 through 2037, while the remaining federal NOLs do not expire. The Company’s state NOLs are scheduled to expire from 2027 through 2040. The Company’s federal and state tax credit carryforwards begin expiring in 2021. For financial reporting purposes, valuation allowances of $48.6 million and $43.4 million at December 31, 2020 and 2019, respectively, have been established to offset deferred tax assets relating primarily to NOLs and research and development credits. The increase in the valuation allowance of $5.3 million for the year ended December 31, 2020 was primarily due to increased operating losses. The Company has established a valuation allowance against its entire net tax asset. As a result, the Company does not recognize any tax benefit until it is in a taxpaying position or there is no longer negative evidence leading to the conclusion that it is more likely than not that the benefits will not be realized. A reconciliation of the Company’s gross unrecognized tax benefits is as follows: Years Ended December 31, 2020 2019 Balance at beginning of year $ 2,731,015 $ 1,538,220 Increases to prior positions — 650,687 Decreases to prior positions (5,694 ) — Increases for current year positions 235,521 542,108 Balance at end of year $ 2,960,842 $ 2,731,015 As of December 31, 2020, the Company had $3.0 million of gross unrecognized tax benefits, related to research and experimental tax credits. The Company had no unrecognized tax benefits as of December 31, 2020, which, if recognized, would affect the annual effective tax rate, due to the full valuation allowance on the deferred tax assets. Although it is possible that the amount of unrecognized benefits with respect to our uncertain tax positions will increase or decrease in the next twelve months, the Company does not expect material changes. The CARES Act contains certain income tax relief provisions, including a modification to the limitation of business interest expense for tax years beginning in 2019 and 2020. In addition, the CARES Act permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021, and allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company does not anticipate any material impacts to its tax status or reporting as a result of these provisions. The Company files income tax returns in the United States, Arizona, California, Texas, various other state jurisdictions, and France ,

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events ATM Offering From January 1 through March 15, 2021, the Company sold approximately 1 million shares of common stock under the ATM Offering at the then-market prices for total gross proceeds of $6.9 million. After sales commissions owed in connection with the ATM Offering, the Company’s aggregate net proceeds from sales of common shares under the ATM Offering during this period were $6.7 million.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In November 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen shares of issued and outstanding common stock were exchanged for one share of common stock. All share and per share amounts within the consolidated financial statements and notes thereto have been adjusted to reflect the reverse stock split for all periods and dates presented. See Note 14 for more information about the Company’s reverse stock split.
Principles of Consolidation	Principles of Consolidation The Company formed a French subsidiary, HTG Molecular Diagnostics France SARL, in November 2018. The consolidated financial statements include the accounts of the Company and this wholly owned subsidiary after elimination of intercompany transactions and balances as of December 31, 2020 and 2019.
Reclassifications	Reclassifications Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.
COVID-19 Pandemic	COVID-19 Pandemic The full impact of the COVID-19 pandemic continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce. Given the ongoing evolution of the COVID-19 pandemic, including resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of the COVID-19 pandemic on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and believes that while it has seen some recovery in the later part of 2020, this impact will continue to be seen at some level at least through the first half of 2021. The extent of this impact varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. The Company has experienced very limited delays in its development efforts because of stay-at-home orders despite its efforts to prioritize the safety of its employees during this pandemic. The Company believes the COVID-19 pandemic will continue to impact its productivity, supply chains, distribution networks and other areas of its operation as ongoing concerns regarding the pandemic continue to disrupt the Company’s business and the businesses of its vendors, partners and customers and as shipping and manufacturing resources are prioritized throughout the world to fight the continued spread of the pandemic . In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID‑19 pandemic. On April 21, 2020, the Company received proceeds from a loan in the amount of $1.7 million from Silicon Valley Bank (“SVB”), as lender, pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act (the “PPP Loan”) (see Note 8). In December 2020, the Consolidated Appropriations Act (the “Appropriations Act”) was signed into law to further address the ongoing impacts of the COVID-19 pandemic. The Appropriations Act introduced several additional potential credits and benefits for employers to consider including, but not limited to, the ability for employers who have previously obtained a PPP Loan to potentially also qualify for the Employee Retention Credit, initially created as part of the CARES Act. The Company expects to qualify for benefits available to it under the Appropriations Act for the year ended December 31, 2020 and will continue to seek out these benefits in future periods as appropriate. While there remains uncertainty as to the ultimate impact of the COVID-19 pandemic, the Company has considered the known impacts on its business as of the date these consolidated financial statements were issued and has reflected any known or expected impacts in its consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position.
Going Concern and Liquidity	Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year after the consolidated financial statements are issued. The consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of the assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $191.2 million as of December 31, 2020. As of December 31, 2020, the Company had working capital of $25.6 million and long-term liabilities of $13.5 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured Loan and Security Agreement (the “Loan Agreement”) with SVB, the PPP Loan, and a commercial financing agreement extending the payment period related to its director and officer insurance policy The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant within the Loan Agreement requiring the Company to maintain unrestricted cash of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates include revenue recognition, stock-based compensation expense, bonus accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory obsolescence and valuation of inventory, accounts receivable and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of the COVID-19 pandemic on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, commercial paper, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable represent valid claims against debtors. Management reviews accounts receivable regularly to determine, using the specific identification method, if any receivable amounts will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value.
Investments in Available-for-Sale Securities	Investments in Available-for-Sale Securities The Company classifies its debt securities as available-for-sale, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive loss, net of tax. Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense) within the consolidated statements of operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest earned on securities is also included in other income (expense) within the consolidated statements of operations. The Company recognizes other-than-temporary impairment (“OTTI”) of a debt security for which there has been a decline in fair value below amortized cost if (i) management intends to sell the security, (ii) it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, or (iii) the Company does not expect to recover the entire amortized cost basis of the security. The amount by which amortized cost exceeds the fair value of a debt security that is considered to have OTTI is separated into a component representing the credit loss, which is recognized in earnings, and a component related to all other factors, which is recognized in other comprehensive income (loss). The measurement of the credit loss component is equal to the difference between the debt security’s amortized cost basis and the present value of its expected future cash flows discounted at the security’s effective yield. If the Company intends to sell the security, or if it is more likely than not it will be required to sell the security before recovery, an OTTI write-down is recognized in earnings equal to the entire difference between the amortized cost basis and fair value of the security .
Restricted Cash	Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows. December 31, 2020 2019 Cash and cash equivalents $ 22,397,812 $ 7,619,748 Restricted cash — 3,270,247 Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 22,397,812 $ 10,889,995 In October 2017, the Company received $3.0 million in gross proceeds from, and issued a subordinated convertible promissory note (the “QNAH Convertible Note”) in that principal amount to, QIAGEN North American Holdings, Inc. (“QNAH”). Amounts included in restricted cash as of December 31, 2019 represented those required to be set aside in escrow under the terms of the MidCap Credit and Security Agreement (Term Loan) (the “MidCap Term Loan”) (see Note 8) to collateralize the payment that would have been due upon maturity of the QNAH Convertible Note (see Note 8). The balance of restricted cash was released to the Company in June 2020 in conjunction with the extinguishment of the QNAH Convertible Note with proceeds from the SVB Term Loan (see Note 8).
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which was determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The NuvoGen obligation relates to an asset purchase transaction with a then-common stockholder of the Company (see Note 10). As of December 31, 2020, the estimated aggregate fair value of the NuvoGen obligation is approximately $4.7 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates.
Inventory, net	Inventory, net Inventory, consisting of raw materials, work in process and finished goods, is stated at the lower of cost (first-in, first-out) or net realizable value. Cost is determined using a standard cost system, whereby the standard costs are updated periodically to reflect current costs. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion and disposal. The Company reserves or writes down its inventory for estimated obsolescence or inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. The period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent rental agreement with the Company after evaluating the product for one year, the equipment is returned to the Company or the customer is allowed to continue use of the equipment, in which case the equipment is written off to selling, general and administrative expense in the consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation as of December 31, 2020 was $50,855 compared with $79,338 as of December 31, 2019.
Property and Equipment, net	Property and Equipment, net Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Equipment used in the field is amortized using the straight-line method over the lesser of the period of the related reagent rental or collaborative development services agreement where applicable or the estimated useful life. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Costs incurred in the development and installation of software for internal use and in the development of the Company’s website are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount of an asset group exceeds its estimated future cash flow, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Although the Company has accumulated losses since inception, the Company believes the future cash flows will be sufficient to exceed the carrying value of the Company’s long-lived assets. There were no impairments of long-lived assets during the years ended December 31, 2020 and 2019.
Leases	Leases Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheets as both a right-of-use asset and lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For financing leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded to rent expense as incurred.
Debt Issuance Costs and Debt Discounts	Debt Issuance Costs and Debt Discounts Costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Costs incurred to issue the MidCap Credit and Security Agreement (Revolving Loan) (the “MidCap Revolving Loan”) were deferred as an asset in the consolidated balance sheets and amortized on a straight-line basis to interest expense over the term of the revolving commitment until extinguishment of the MidCap Credit and Security Agreement in June 2020 (see Note 8) .
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs represent legal and other direct costs related to planned future stock offering transactions that will be charged to stockholders’ equity upon completion of the proposed stock offering. Should the proposed stock offering prove to be unsuccessful, these deferred costs, as well as any additional expenses to be incurred, will be charged to operating expense in the consolidated statements of operations. There were no deferred offering costs for the year ended December 31, 2020. Deferred offering costs of $0.1 million included as non-current assets in the consolidated balance sheet as of December 31, 2019, represented legal costs incurred by the Company in contemplation of the issuance of additional shares in a future financing transaction. In January 2020, these deferred offering costs were recorded to additional paid in capital, as an offset to proceeds received from the ATM Offering (see Note 14).
Contract Liabilities	Contract Liabilities Contract liabilities represent cash receipts for products or services to be delivered in future periods, including up-front fees received relating to custom RUO assay design and collaborative development services. When products or services are delivered to customers, contract liabilities are recognized as earned. Up-front fees received for custom RUO assay design or collaborative development services are recognized over time based on the costs incurred to date compared with total expected costs as design or development procedures are completed and outputs are produced.
Revenue Recognition	Revenue Recognition The Company accounts for its revenue in accordance with FASB, ASC 606, Revenue from Contracts with Customers Collaborative Arrangements For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company has made a policy election to exclude from the measurement of the transaction price all taxes assessed by a government authority that are both imposed on and concurrent with a specific revenue producing transaction and collected by the Company from a customer. Such taxes may include but are not limited to sales, use, value added and certain excise taxes. See Note 9 for additional discussion of the Company’s revenue recognition policies.
Product Warranty	Product Warranty The Company generally provides a one-year warranty on its HTG EdgeSeq platform covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. A provision for estimated warranty costs is recognized at the time of sale, through cost of product and product-related services revenue, based upon recent historical experience and other relevant information as it becomes available. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and adjusts the provision as needed. Warranty accrual is included in accrued liabilities in the consolidated balance sheets.
Research and Development Expenses	Research and Development Expenses Research and development expenses represent costs incurred internally for and externally in support of research and development activities. These costs include those generated through research and development efforts for the improvement and expansion of the Company’s proprietary technology and product offerings as well as those related to third-party collaborative development agreements, for which related revenue is included in collaborative development services revenue in the consolidated statements of operations. See for further discussion of the development costs associated with collaborative development services agreements included in research and development expense in the consolidated statements of operations.
Stock-based Compensation	Stock-based Compensation The Company incurs stock-based compensation expense relating to grants of restricted stock units (“RSUs”) and stock options to employees, consultants and non-employee directors under its equity incentive plans, and stock purchase rights granted under its Employee Stock Purchase Plan (“ESPP”). The Company recognizes expense for stock-based awards based on the fair value of awards on the date of grant. The fair value of RSUs is based on the quoted market price of the Company’s common stock on the date of grant. The fair value of ESPP rights and stock options granted pursuant to the Company’s equity incentive plans is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value utilizing the Black-Scholes option pricing model is affected by the fair value of the Company’s stock price and several assumptions, including volatility, expected term, risk-free interest rate, and dividend yield. Generally, these assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. The Company accounts for forfeitures as they occur.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts and tax base of assets and liabilities using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established against net deferred tax assets for the uncertainty it presents of our ability to use the net deferred tax assets, in this case, primarily carryforwards of net operating tax losses and research and development tax credits. In assessing the realizability of net deferred tax assets we have assessed the likelihood that net deferred tax assets will be recovered from future taxable income, and to the extent that it is “more likely than not” that the assets will not be recovered or there is an insufficient history of operating profits, a valuation allowance is established. We record the valuation allowance in the period we determine that it is more likely than not that net deferred tax assets will not be realized. For the years ended December 31, 2020 and 2019, we have provided a full valuation allowance for all net deferred tax assets due to their current realization being considered remote in the near term. Uncertain tax positions taken or expected to be taken in a tax return are accounted for using the more likely than not threshold for financial statement recognition and measurement.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The Company has assets and liabilities, including accounts receivable and accounts payable, which are denominated in currencies other than its functional currency. These assets and liabilities are subject to re-measurement, the impact of which is recorded in selling, general and administrative expense within the consolidated statements of operations. Adjustments resulting from translating foreign functional currency financial statements of the Company’s wholly owned subsidiary into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss in the consolidated statements of changes in stockholder’s equity.
Comprehensive Loss	Comprehensive Loss Comprehensive loss includes certain changes in equity that are excluded from net loss. Specifically, unrealized gains and losses on short-term available-for-sale investments and adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in comprehensive loss.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top customer accounted for 11% of revenue for the year ended December 31, 2020, compared with the top three customers which accounted for 24%, 22% and 19% for the year ended December 31, 2019. The largest two customers accounted for approximately 9% each of the Company’s net accounts receivable as of December 31, 2020. The largest two customers accounted for approximately 29% and 25% of the Company’s net accounts receivable at December 31, 2019. Two vendors accounted for 21% and 20% of the Company’s accounts payable as of December 31, 2020 primarily related to commercial operations and inventory purchases compared with one vendor who accounted for 36% and two vendors who accounted for 10% each of the Company’s accounts payable at December 31, 2019. The Company currently relies on a single supplier to manufacture a subcomponent used in its HTG EdgeSeq instruments. A loss of this supplier could significantly delay the delivery of products, which in turn would materially affect the Company’s ability to generate revenue.
Recently Adopted and New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement In November 2018, the FASB issued ASU No. 2018-18, which amended ASC 808, Collaborative Arrangements Recent Accounting Pronouncements The following are recent FASB ASUs that had not been adopted by the Company as of December 31, 2020: In October 2020, the FASB issued ASC Update No. 2020-10, Codification Improvements In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options Derivatives and Hedging – Contracts in Entity’s Own Equity Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects of the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This standard is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2020. The Company does not expect the adoption of the new guidance under the standard to materially affect its financial position or results of operations. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows. December 31, 2020 2019 Cash and cash equivalents $ 22,397,812 $ 7,619,748 Restricted cash — 3,270,247 Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows $ 22,397,812 $ 10,889,995

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the date indicated: December 31, 2020 2019 Raw materials $ 1,079,528 $ 872,947 Work in process 147,455 151,351 Finished goods 291,195 284,772 Total gross inventory 1,518,178 1,309,070 Less inventory allowance $ (26,052 ) $ (39,403 ) $ 1,492,126 $ 1,269,667

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets measured at fair value on a recurring basis at December 31, 2020 and 2019, respectively, in the fair value hierarchy: December 31, 2020 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 17,497,282 $ — $ — $ 17,497,282 Corporate debt securities — 4,499,270 — 4,499,270 Investments available-for-sale at fair value Corporate debt securities — 6,298,075 — 6,298,075 Total $ 17,497,282 $ 10,797,345 $ — $ 28,294,627 December 31, 2019 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 7,217,096 $ — $ — $ 7,217,096 Investments available-for-sale at fair value U.S. Treasury securities 5,961,983 — — 5,961,983 Corporate debt securities — 19,448,239 — 19,448,239 Total $ 13,179,079 $ 19,448,239 $ — $ 32,627,318

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	12 Months Ended
	Dec. 31, 2020
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The Company’s portfolio of available-for-sale securities consists of high credit quality corporate debt securities as of December 31, 2020. The following is a summary of the Company’s available-for-sale securities at December 31, 2020 and 2019: December 31, 2020 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 6,298,075 — — 6,298,075 Total available-for-sale securities $ 6,298,075 $ — $ — $ 6,298,075 December 31, 2019 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) U.S. Treasury securities $ 5,962,224 $ 394 $ (635 ) $ 5,961,983 Corporate debt securities 19,448,239 — - 19,448,239 Total available-for-sale securities $ 25,410,463 $ 394 $ (635 ) $ 25,410,222
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities at December 31, 2020 are shown below. Under 1 Year 1 to 2 Years Total Corporate debt securities 6,298,075 — 6,298,075 Total available-for-sale securities $ 6,298,075 $ — $ 6,298,075

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net consists of the following as of the dates indicated: December 31, 2020 2019 Furniture & fixtures $ 1,082,717 $ 1,089,371 Leasehold improvements 1,943,534 1,987,997 Equipment used in manufacturing 2,166,743 2,305,340 Equipment used in research & development 2,506,644 2,134,019 Equipment used in the field 208,005 182,762 Software 420,301 374,812 Property and equipment 8,327,944 8,074,301 Less: accumulated depreciation and amortization (7,100,542 ) (5,834,168 ) $ 1,227,402 $ 2,240,133

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consist of the following as of the dates indicated: December 31, 2020 2019 Accrued employee bonuses $ 436,799 $ 900,740 Payroll and employee benefit accruals 694,058 469,530 Accrued interest 61,676 245,350 Other accrued liabilities 267,345 254,676 $ 1,459,878 $ 1,870,296

Debt Obligations (Tables)

Debt Obligations (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Current Portion of Long-term Debt, Net	Current portion of long-term debt, net, consists of the following as of the dates indicated: December 31, 2020 2019 Convertible note, net of debt issuance costs $ — $ 2,987,667 SVB Term Loan payable 2,000,000 — PPP Loan 857,040 — Insurance Note Payable 165,099 — $ 3,022,139 $ 2,987,667
Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs	Long-term debt, net of current portion and discount and debt issuance costs, consisted of the following as of the dates indicated: December 31, 2020 2019 MidCap Term Loan payable, net of discount and debt issuance costs $ — $ 6,871,545 SVB Term Loan payable, net of discount and debt issuance costs 7,708,348 — PPP Loan 859,960 — $ 8,568,308 $ 6,871,545
Schedule of Remaining Principal Repayments due Under SVB Term Loan	The remaining principal repayments due under the SVB Term Loan as of December 31, 2020 are as follows for each fiscal year: 2021 $ 2,000,000 2022 4,000,000 2023 4,000,000 Total SVB Term Loan payments 10,000,000 Less discount and deferred financing costs (1,091,652 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 9,708,348

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Product and Product-Related Service Revenue from Sale of Instruments and Consumables	Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the years ended December 31, 2020 and 2019 as follows: Years Ended December 31, 2020 2019 Product revenue: Instrument $ 869,035 $ 1,436,730 Consumables 3,030,612 3,010,094 Total product revenue 3,899,647 4,446,824 Product-related services revenue: Custom RUO assay design 1,393,316 4,498,088 RUO sample processing 2,597,891 5,687,292 Total product-related services revenue 3,991,207 10,185,380 Total product and product-related services revenue $ 7,890,854 $ 14,632,204
Schedule of Collaborative Development Services	Collaborative Development Services Revenue The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. Collaborative development services revenue related to these contracts for the years ended December 31, 2020 and 2019 was generated through statements of work entered into under the Governing Agreement with QIAGEN Manchester Limited (“QML”) as discussed below. Years Ended December 31, 2020 2019 Collaborative development services $ 658,010 $ 4,571,684
Schedule of Changes in Contract Liability	Changes in the Company’s contract liabilities were as follows as of the dates indicated: Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2020 $ 95,148 $ 66,216 $ 438,090 $ 599,454 Deferral of revenue 500,045 566,733 124,404 1,191,182 Recognition of deferred revenue (491,613 ) (632,949 ) (186,888 ) (1,311,450 ) Transfer to refund liability — — (281,722 ) (281,722 ) Balance at December 31, 2020 $ 103,580 $ — $ 93,884 $ 197,464 Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2019 $ 116,547 $ 50,000 $ 244,400 $ 410,947 Deferral of revenue 218,802 972,267 529,913 1,720,982 Recognition of deferred revenue (240,201 ) (956,051 ) (336,223 ) (1,532,475 ) Balance at December 31, 2019 $ 95,148 $ 66,216 $ 438,090 $ 599,454

Other Agreements (Tables)

Other Agreements (Tables)	12 Months Ended
	Dec. 31, 2020
Other Agreements [Abstract]
Schedule of Remaining Minimum Principal Payments Due	Minimum payments to be made in 2021 include $54,777 of revenue-based payments payable as of December 31, 2020 and an estimate of additional revenue-based payments to be made throughout the remainder of 2021 relating to revenue generated in the first, second and third quarters of 2021 using actual revenue generated in the same quarters in 2020. Minimum payments for the remaining years include only the minimum payments for each year. Actual payments could be significantly more than provided in the table, to the extent that 6% of the Company’s annual revenue in those years exceeds $0.4 million: 2021 $ 512,729 2022 400,000 2023 400,000 2024 400,000 2025 400,000 2025 and beyond 2,800,021 Total NuvoGen obligation payments 4,912,750 Plus interest accretion 79,376 Total NuvoGen obligation, net $ 4,992,126

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Summary of Components of Lease Cost	The components of lease cost for operating leases were as follows: Years Ended December 31, 2020 2019 Operating leases Operating lease cost $ 752,413 $ 618,463 Variable lease cost 125,792 131,387 Operating lease expense 878,205 749,850 Short-term lease rent expense — 1,497 Total rent expense $ 878,205 $ 751,347 Years Ended December 31, 2020 2019 Financing leases Amortization of right-of-use assets $ 42,826 $ 46,255 Interest on lease liability 8,938 6,859 Total financing lease cost $ 51,764 $ 53,114
Summary of Other Information Related to Operating Leases	The table below summarizes other information related to the Company’s operating leases: Years Ended December 31, 2020 2019 Cash paid for amounts included in measurement of operating lease liabilities $ 883,252 $ 770,658 Establishment of operating lease liabilities arising from obtaining right-of-use assets $ 515,409 $ 2,038,193 Weighted-average remaining lease term – operating leases 1.7 2.3 Weighted-average discount rate – operating leases 8.0 % 9.6 %
Summary of Remaining Maturities of Operating Leases, Excluding Short-term Leases	As of December 31, 2020, remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows: 2021 $ 746,724 2022 319,678 2023 70,848 Total 1,137,250 Less present value discount (83,348 ) Total operating lease liabilities 1,053,902 Less operating lease liabilities - current (685,220 ) Non-current operating lease liabilities - non-current $ 368,682
Summary of Other Information Related to Financing Leases	The table below summarizes other information related to the Company’s financing leases: Years Ended December 31, 2020 2019 Weighted-average remaining lease term – financing leases 3.4 3.7 Weighted-average discount rate – financing leases 9.77 % 9.77 %
Summary of Remaining Maturities of Financing Leases	As of December 31, 2020, remaining maturities of the Company’s financing leases are as follows: 2021 $ 28,355 2022 20,716 2023 18,396 2024 16,080 Total 83,547 Less present value discount (12,873 ) Financing lease liabilities, net $ 70,674

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Years Ended December 31, 2020 2019 Numerator: Net loss $ (20,870,218 ) $ (19,297,664 ) Denominator: Weighted-average shares outstanding-basic and diluted * 4,627,918 2,539,979 Net loss per share, basic and diluted $ (4.51 ) $ (7.60 )
Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share	The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Years Ended December 31, 2020 2019 Options to purchase common stock 487,227 193,660 Series A Preferred 158,545 — Common stock warrants 58,689 15,794 Restricted stock units 12,214 14,916 QNAH convertible note — 53,357

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Outstanding Warrants	The following table shows the common stock warrants outstanding as of December 31, 2020: Warrant Issuance Date Shares of Common Underlying Warrants Exercise Price/Share Expiration Date August 2014 1,914 $ 352.65 2024 December 2014 9,651 210.00 2022 March 2016 3,021 41.40 2026 March 2018 1,208 115.95 2028 September 2019 148,995 0.15 N/A June 2020 42,894 11.6565 2030

Stockholders Equity (Tables)

Stockholders Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Summary of Stock Based Compensation Recognized in Consolidated Statement of Operations	Amounts recognized in the consolidated statements of operations with respect to the Company’s equity incentive plans were as follows: Years Ended December 31, 2020 2019 Selling, general and administrative $ 1,461,190 $ 859,653 Research and development 106,267 243,804 Cost of product and product-related services revenue 17,328 53,110 $ 1,584,785 $ 1,156,567
Summary of Stock Option Plans Activity	The following table summarizes stock option activity during the two-year period ended December 31, 2020: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at January 1, 2019 136,482 $ 46.05 7.6 $ 366,007 Granted 84,667 22.20 Exercised (3,617 ) 33.45 $ 21,380 Forfeited (10,771 ) 49.35 Expired/Cancelled (13,101 ) 48.45 Balance at December 31, 2019 193,660 $ 35.55 8.0 $ 781 Granted 387,178 7.81 Exercised - - $ - Forfeited (67,369 ) 12.99 Expired/Cancelled (26,242 ) 32.04 Balance at December 31, 2020 487,227 $ 16.78 8.6 $ 1,536 Exercisable at December 31, 2019 92,058 42.60 6.6 $ 1,440 Exercisable at December 31, 2020 187,031 27.07 7.5 $ 305
Summary of Material Factors Incorporated in Black-Scholes Model In Estimating Fair Value of Options Granted	The material factors incorporated in the Black-Scholes model in estimating the fair value of the stock options granted for the periods presented were as follows: 2020 2019 Fair value of common stock on grant date $4.35 - 11.25 $10.20 - 33.90 Risk-free interest rate 0.34% - 1.65% 1.43% - 2.21% Expected volatility 109.1% - 149.9% 63.9% - 97.1% Expected term 5.4 to 5.9 years 5.5 to 6.1 years Expected dividend yield 0% 0%
Summary of Restricted Stock Unit (RSU) Plans Activity	The following table summarizes RSU award activity during the two-year period ended December 31, 2020: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at January 1, 2019 15,180 $ 49.50 Granted 5,167 28.95 Released (5,431 ) 49.65 Balance at December 31, 2019 14,916 $ 43.65 Granted 7,000 7.83 Released (7,911 ) 35.85 Forfeited (1,791 ) 41.23 Balance at December 31, 2020 12,214 $ 28.61 Vested and unissued at December 31, 2020 1,390 $ 33.21
Employee Stock Purchase Plan
Summary of Stock Based Compensation Recognized in Consolidated Statement of Operations	Amounts recognized in the consolidated statements of operations with respect to the ESPP were as follows: Years Ended December 31, 2020 2019 Selling, general and administrative $ 12,106 $ 43,615 Research and development 5,248 18,454 Cost of product and product-related services revenue 3,832 4,169 $ 21,186 $ 66,238
Summary of Material Factors Incorporated in Black-Scholes Model In Estimating Fair Value of Options Granted	The material factors incorporated in the Black-Scholes model in estimating the fair value of the ESPP awards for the periods presented were as follows: 2020 2019 Fair value of common stock $8.70 - 9.75 $27.75 - 60.00 Risk-free interest rate 0.18% - 1.58% 1.88% - 2.37% Expected volatility 65.8% - 88.9% 79.5% - 85.8% Expected term 0.5 years 0.5 years Expected dividend yield 0% 0%
Summary of Shares Purchased under ESPP'S Six Month Purchase Periods	During the year ended December 31, 2020, employees entering the plan at various times throughout the offering period purchased the following shares at the end of each of the ESPP’s six-month purchase periods: June 2020 December 2020 Number of Shares Price per Share Number of Shares Price per Share ESPP Group: Group A 3,033 $ 8.29 2,857 $ 4.87 Group B - N/A 396 4.87 Total number of shares purchased 3,033 3,253 During the year ended December 31, 2019, employees entering the plan at various times throughout the offering period purchased the following shares at the end of each of the ESPP’s six-month purchase periods: June 2019 December 2019 Number of Shares Price per Share Number of Shares Price per Share ESPP Group: Group A 1,972 $ 23.59 1,830 $ 8.55 Group B 389 26.78 349 8.55 Group C 305 26.78 320 8.55 Group D - N/A 165 8.55 Total number of shares purchased 2,666 2,664

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability, which is included in accrued liabilities in the consolidated balance sheets for the years ended December 31, 2020 and 2019: Years Ended December 31, 2020 2019 Beginning balance $ 94,482 $ 63,461 Cost of warranty claims (32,866 ) (40,055 ) Increase in warranty reserve 31,080 71,076 Ending balance $ 92,696 $ 94,482

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Summary of Loss Before Income taxes	The following table summarizes loss before income taxes: Years Ended December 31, 2020 2019 U.S. pre-tax loss $ (20,855,184 ) $ (19,332,809 ) Foreign pre-tax gain (loss) (619 ) 38,524 Loss before income taxes $ (20,855,803 ) $ (19,294,285 )
Components of Income Tax Expense	The components of income tax expense are as follows: Years Ended December 31, 2020 2019 Current: Federal $ — $ — State 10,860 3,379 Foreign 3,555 — Total current income tax expense $ 14,415 $ 3,379 Deferred: Federal $ — $ — State — — Foreign — — Total deferred income tax expense $ — $ — Total income tax expense $ 14,415 $ 3,379
Schedule of Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes	The Company’s actual income tax expense for the years ended December 31, 2020 and 2019 differ from the expected amount computed by applying the statutory federal income tax rate to loss before income taxes as follows: Years Ended December 31, 2020 2019 Computed tax (benefit) at 21% $ (4,379,719 ) $ (4,051,800 ) State taxes, net of federal benefit (832,055 ) (881,670 ) Stock-based compensation 310,811 183,167 Foreign tax rate differential 3,685 4,298 Return to provision 26,120 80,668 Other 31,850 51,737 Research and development tax credit - state (218,991 ) (342,320 ) Research and development tax credit - federal (197,836 ) (301,878 ) Uncertain tax position adjustment for prior periods (5,694 ) 650,687 Increase in valuation allowance 5,276,244 4,610,490 $ 14,415 $ 3,379
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities comprise the following: Years Ended December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 43,308,483 $ 38,357,970 Research and development credits 3,475,341 3,061,981 Deferred revenue 50,429 154,497 Inventory reserve 6,653 10,155 Fixed assets and intangibles 313,117 217,332 Accrued NuvoGen liability 1,274,896 1,456,435 Lease liability 269,147 359,603 Other 211,574 150,134 Gross deferred tax assets 48,909,640 43,768,107 Valuation allowance (48,626,925 ) (43,350,682 ) Deferred tax assets, net 282,715 417,425 Deferred tax liabilities: Right of use asset 257,705 311,633 Other 25,010 105,792 Total deferred tax liabilities 282,715 417,425 Net deferred tax assets (liabilities) $ - $ -
Schedule of Reconciliation of Gross Unrecognized Tax Benefits	A reconciliation of the Company’s gross unrecognized tax benefits is as follows: Years Ended December 31, 2020 2019 Balance at beginning of year $ 2,731,015 $ 1,538,220 Increases to prior positions — 650,687 Decreases to prior positions (5,694 ) — Increases for current year positions 235,521 542,108 Balance at end of year $ 2,960,842 $ 2,731,015

Description of Business, Basi_2

Description of Business, Basis of Presentation and Principles of Consolidation - Additional Information (Details)	Nov. 20, 2020	Apr. 21, 2020USD ($)	Nov. 30, 2020	Dec. 31, 2020USD ($)Segment	Dec. 31, 2019USD ($)
Significant Accounting Policies [Line Items]
Number of operating segments | Segment				1
Stock split conversion ratio	0.067
Reverse stock split, description	On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen (15) shares of issued and outstanding common stock were exchanged for one share of its common stock.
Proceeds from PPP Loan				$ 1,717,000
Accumulated deficit				(191,187,861)	$ (170,317,643)
Working Capital				25,600,000
Long-term liabilities				13,500,000
Debt instrument, covenant unrestricted cash				$ 12,500,000
Paycheck Protection Program Loan | Silicon Valley Bank
Significant Accounting Policies [Line Items]
Proceeds from PPP Loan		$ 1,700,000
Common Stock
Significant Accounting Policies [Line Items]
Stock split conversion ratio			0.15
Reverse stock split, description				In November 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen shares of issued and outstanding common stock were exchanged for one share of common stock.
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage				35.00%	34.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	1 Months Ended	12 Months Ended
	Oct. 31, 2017USD ($)	Dec. 31, 2020USD ($)CustomerVendor	Dec. 31, 2019USD ($)CustomerVendor
Significant Accounting Policies [Line Items]
Maturity period of investments		less than one year
Finished goods inventory		$ 291,195	$ 284,772
Impairment of Long-lived assets		0	0
Deferred offering costs, current		$ 0	$ 100,000
ASU 2018-13
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted		true
Change in accounting principle, accounting standards update, adoption date		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect		true
ASU 2018-18
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted		true
Change in accounting principle, accounting standards update, adoption date		Jan. 1, 2020
Change in accounting principle, accounting standards update, immaterial effect		true
Supplier Concentration Risk | Accounts Payable
Significant Accounting Policies [Line Items]
Number of vendors | Vendor		2	3
Supplier Concentration Risk | Accounts Payable | Vendor One
Significant Accounting Policies [Line Items]
Sales revenue percentage		21.00%	36.00%
Supplier Concentration Risk | Accounts Payable | Vendor Two
Significant Accounting Policies [Line Items]
Sales revenue percentage		20.00%	10.00%
Supplier Concentration Risk | Accounts Payable | Vendor Three
Significant Accounting Policies [Line Items]
Sales revenue percentage			10.00%
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer			3
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage		11.00%	24.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			22.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage			19.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer		2	2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage		9.00%	29.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage		9.00%	25.00%
Software and Software Development Costs
Significant Accounting Policies [Line Items]
Long-term asset, estimated life		3 years
Minimum
Significant Accounting Policies [Line Items]
Period of time customers use to evaluate the Company's equipment		90 days
Long-term asset, estimated life		3 years
Maximum
Significant Accounting Policies [Line Items]
Period of time customers use to evaluate the Company's equipment		180 days
Long-term asset, estimated life		5 years
NuvoGen Asset Purchase Agreement
Significant Accounting Policies [Line Items]
Convertible debt, fair value		$ 4,700,000
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Significant Accounting Policies [Line Items]
Gross proceeds from issuance of subordinated notes	$ 3,000,000
HTG EdgeSeq
Significant Accounting Policies [Line Items]
Finished goods inventory		$ 50,855	$ 79,338

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 22,397,812	$ 7,619,748
Restricted cash		3,270,247
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 22,397,812	$ 10,889,995

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 1,079,528	$ 872,947
Work in process	147,455	151,351
Finished goods	291,195	284,772
Total gross inventory	1,518,178	1,309,070
Less inventory allowance	(26,052)	(39,403)
Inventory, net	$ 1,492,126	$ 1,269,667

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Provision for excess inventory	$ 56,160	$ 153,729

Fair Value - Financial Assets a

Fair Value - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Asset included in:
Investments available-for-sale at fair value	$ 6,298,075	$ 25,410,222
Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	6,298,075	19,448,239
U.S. Treasury Securities
Asset included in:
Investments available-for-sale at fair value		5,961,983
Fair Value, Measurements, Recurring
Asset included in:
Financial Assets	28,294,627	32,627,318
Fair Value, Measurements, Recurring | Money Market Securities
Asset included in:
Cash and cash equivalents	17,497,282	7,217,096
Fair Value, Measurements, Recurring | Corporate Debt Securities
Asset included in:
Cash and cash equivalents	4,499,270
Investments available-for-sale at fair value	6,298,075	19,448,239
Fair Value, Measurements, Recurring | U.S. Treasury Securities
Asset included in:
Investments available-for-sale at fair value		5,961,983
Fair Value, Measurements, Recurring | Level 1
Asset included in:
Financial Assets	17,497,282	13,179,079
Fair Value, Measurements, Recurring | Level 1 | Money Market Securities
Asset included in:
Cash and cash equivalents	17,497,282	7,217,096
Fair Value, Measurements, Recurring | Level 1 | U.S. Treasury Securities
Asset included in:
Investments available-for-sale at fair value		5,961,983
Fair Value, Measurements, Recurring | Level 2
Asset included in:
Financial Assets	10,797,345	19,448,239
Fair Value, Measurements, Recurring | Level 2 | Corporate Debt Securities
Asset included in:
Cash and cash equivalents	4,499,270
Investments available-for-sale at fair value	$ 6,298,075	$ 19,448,239

Fair Value - Additional Informa

Fair Value - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 6,298,075	$ 25,410,463
Gross Unrealized Gains		394
Gross Unrealized Losses	0	(635)
Fair Value (Net Carrying Amount)	6,298,075	25,410,222
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		5,962,224
Gross Unrealized Gains		394
Gross Unrealized Losses		(635)
Fair Value (Net Carrying Amount)		5,961,983
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	6,298,075	19,448,239
Fair Value (Net Carrying Amount)	$ 6,298,075	$ 19,448,239

Available-for-Sale Securities_2

Available-for-Sale Securities - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Investments Debt And Equity Securities [Abstract]
Available-for-sale securities investments, gross unrealized losses	$ 0	$ 635
Unrealized gain on short-term investments	9	$ 2,299
Other-than-temporary impairment	$ 0

Available-for-Sale Securities_3

Available-for-Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 6,298,075
Fair Value (Net Carrying Amount)	6,298,075	$ 25,410,222
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	6,298,075
Fair Value (Net Carrying Amount)	$ 6,298,075	$ 19,448,239

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Furniture & fixtures	$ 1,082,717	$ 1,089,371
Leasehold improvements	1,943,534	1,987,997
Equipment used in manufacturing	2,166,743	2,305,340
Equipment used in research & development	2,506,644	2,134,019
Equipment used in the field	208,005	182,762
Software	420,301	374,812
Property and equipment	8,327,944	8,074,301
Less: accumulated depreciation and amortization	(7,100,542)	(5,834,168)
Property and equipment, net	$ 1,227,402	$ 2,240,133

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 1,346,560	$ 1,259,015

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued employee bonuses	$ 436,799	$ 900,740
Payroll and employee benefit accruals	694,058	469,530
Accrued interest	61,676	245,350
Other accrued liabilities	267,345	254,676
Total accrued liabilities	$ 1,459,878	$ 1,870,296

Debt Obligations - Schedule of

Debt Obligations - Schedule of Current Portion of Long Term Debt, Net (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Convertible note, net of debt issuance costs		$ 2,987,667
Insurance Note Payable	$ 165,099
Current portion of long-term debt, net	3,022,139	$ 2,987,667
SVB Term Loan
Debt Instrument [Line Items]
SVB Term Loan payable	2,000,000
PPP Loan
Debt Instrument [Line Items]
PPP Loan	$ 857,040

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Debt Instrument [Line Items]
Long term debt non current	$ 8,568,308	$ 6,871,545
SVB Term Loan
Debt Instrument [Line Items]
Loan payable, net of discount and debt issuance costs	7,708,348
PPP Loan
Debt Instrument [Line Items]
PPP Loan	$ 859,960
MidCap Credit Facility
Debt Instrument [Line Items]
Loan payable, net of discount and debt issuance costs		$ 6,871,545

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details)	Jun. 25, 2020USD ($)	Jun. 24, 2020USD ($)$ / sharesshares	Apr. 27, 2020USD ($)	Apr. 21, 2020USD ($)	Mar. 26, 2018USD ($)Institution	Feb. 29, 2020	Oct. 31, 2017USD ($)	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)	Jul. 11, 2018USD ($)
Debt Instrument [Line Items]
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note								$ (522,394)
Warrant purchase price | $ / shares								$ 11.6565
Proceeds from Paycheck Protection Program Loan								$ 1,717,000
Insurance Note
Debt Instrument [Line Items]
Debt instrument, interest rate			3.61%
Loan repayment start date			Jun. 6, 2020
Loan term			9 months
Loan prepayment penalties			$ 0
Down payment on insurance note			200,000
Premium payable on insurance note			$ 700,000
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Debt Instrument [Line Items]
Gross proceeds from issuance of subordinated notes							$ 3,000,000
Debt instrument, interest rate							3.00%
Debt instrument, maturity date							Oct. 26, 2020
Repayments of aggregate amount	$ 3,200,000
SVB Term Loan
Debt Instrument [Line Items]
Unamortized debt discount								1,091,652
Debt instrument, amortization expense								$ 200,000
Debt instrument, interest rate		5.75%
Debt instrument, maturity date		Dec. 1, 2023
Debt instrument, principal amount		$ 10,000,000
Extend the interest-only payments		6 months
Debt instrument early termination fee percentage		3.00%
Debt instrument second anniversary early termination fee percentage		2.00%
Debt instrument after second anniversary early termination fee percentage		1.00%
Debt instrument final payment percentage		8.00%
Debt instrument, covenants unrestricted cash		$ 12,500,000
Debt instrument increase in interest on obligation percentage		5.00%
Warrant to purchase common stock, shares | shares		42,894
Warrant purchase price | $ / shares		$ 11.6565						$ 11.6565
Warrant expiration date		Jun. 24, 2030
Fair value of warrants		$ 400,000
Debt instrument effective interest rate								11.11%
SVB Term Loan | Prime Rate | Minimum
Debt Instrument [Line Items]
Debt instrument, interest at floating rate		2.50%
Paycheck Protection Program Loan
Debt Instrument [Line Items]
Debt instrument, interest rate				1.00%
Debt instrument, maturity date				Apr. 21, 2022
Loan repayment start date				Sep. 21, 2021
Loan term				8 months
Loan prepayment penalties				$ 0
Payroll compensation cost maximum exemption limit				100,000
Paycheck Protection Program Loan | Silicon Valley Bank
Debt Instrument [Line Items]
Proceeds from Paycheck Protection Program Loan				$ 1,700,000
Paycheck Protection Program Loan | Minimum
Debt Instrument [Line Items]
Annual salary reduction rate				25.00%
Paycheck Protection Program Loan | Maximum
Debt Instrument [Line Items]
Percentage of non-payroll costs forgiven				40.00%
Salaries and wages				$ 100,000
MidCap Credit Facility
Debt Instrument [Line Items]
Credit facility aggregate principal amount					$ 20,000,000
Number of loan lending institutions | Institution					2
Debt instrument interest only payment period						11 months
Debt Instrument, Frequency of Periodic Payment								25 equal monthly installments
Debt instrument interest only payment period if revenue milestone achieved						4 months
Amount required to deposit in escrow account					$ 3,300,000
Escrow deposit										$ 3,300,000
Unamortized debt discount									$ 443,455
Debt instrument, amortization expense								$ 93,719	166,904
Repayment of outstanding principal and interest	$ 7,500,000							7,438,623
MidCap Credit Facility | QIAGEN North American Holdings, Inc.
Debt Instrument [Line Items]
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note								500,000
Unamortized discounts								$ 300,000
MidCap Credit Facility | MidCap Tranche 1
Debt Instrument [Line Items]
Credit facility aggregate principal amount					$ 7,000,000
Line of credit facility interest rate					7.25%
Debt instrument, interest at floating rate					1.25%
Credit facility, basis spread on variable rate description					one-month LIBOR
Debt instrument frequency of periodic payment if revenue milestone achieved								21 equal monthly installments
Revolving Credit Facility
Debt Instrument [Line Items]
Unamortized debt discount								$ 0
Revolving loan cost									50,970
Amortization of deferred financing costs								$ 7,763	$ 16,098

Debt Obligations - Schedule o_3

Debt Obligations - Schedule of Remaining Principal Repayments due Under SVB Term Loan (Details) - SVB Term Loan	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
2021	$ 2,000,000
2022	4,000,000
2023	4,000,000
Total SVB Term Loan payments	10,000,000
Less discount and deferred financing costs	(1,091,652)
Plus final fee premium	800,000
Total SVB Term Loan, net	$ 9,708,348

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Product and Product-Related Service Revenue from Sale of Instruments and Consumables (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 8,548,864	$ 19,203,888
Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	7,890,854	14,632,204
HTG EdgeSeq | Instrument
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	869,035	1,436,730
HTG EdgeSeq | Consumables
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	3,030,612	3,010,094
HTG EdgeSeq | Product revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	3,899,647	4,446,824
HTG EdgeSeq | Custom RUO assay design
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	1,393,316	4,498,088
HTG EdgeSeq | RUO Sample processing
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	2,597,891	5,687,292
HTG EdgeSeq | Product-related services revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	3,991,207	10,185,380
HTG EdgeSeq | Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 7,890,854	$ 14,632,204

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation Of Revenue [Line Items]
Agreements for product and product-related services revenue, description	The Company’s agreements for product and product-related services revenue have an expected duration of one year or less
Service revenue	$ 8,548,864	$ 19,203,888
Profit sharing payments	3,991,532	8,911,372
Accounts receivable	1,588,767	3,164,176
Research and development	6,079,907	10,570,225
Contract liabilities	197,464	599,454	$ 410,947
SOW Two
Disaggregation Of Revenue [Line Items]
Accounts receivable	100,000	200,000
Research and development	500,000	1,800,000
SOW Three
Disaggregation Of Revenue [Line Items]
Accounts receivable		800,000
Research and development		1,000,000
Custom RUO Assay Design and Related Agreements
Disaggregation Of Revenue [Line Items]
Revenue recognized	0	41,137
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Service revenue	658,010	4,571,684
Collaborative Development Services | SOW Two
Disaggregation Of Revenue [Line Items]
Service revenue	700,000	2,700,000
Profit sharing payments	200,000	700,000
Collaborative Development Services | SOW Three
Disaggregation Of Revenue [Line Items]
Service revenue	$ 0	1,900,000
Profit sharing payments		$ 700,000
Minimum
Disaggregation Of Revenue [Line Items]
Customer payment term	30 days
Maximum
Disaggregation Of Revenue [Line Items]
Customer payment term	90 days
Maximum | QIAGEN Manchester Limited
Disaggregation Of Revenue [Line Items]
Term of agreement	1 year

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Additional Information1 (Details)	Dec. 31, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2021-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Schedule of Collaborative Development Services (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Service revenue	$ 8,548,864	$ 19,203,888
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Service revenue	$ 658,010	$ 4,571,684

Revenue from Contracts with C_7

Revenue from Contracts with Customers - Schedule of Changes in Contract Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disaggregation Of Revenue [Line Items]
Beginning Balance	$ 599,454	$ 410,947
Deferral of revenue	1,191,182	1,720,982
Recognition of deferred revenue	(1,311,450)	(1,532,475)
Transfer to refund liability	(281,722)
Ending Balance	197,464	599,454
Product Revenue
Disaggregation Of Revenue [Line Items]
Beginning Balance	95,148	116,547
Deferral of revenue	500,045	218,802
Recognition of deferred revenue	(491,613)	(240,201)
Ending Balance	103,580	95,148
Custom RUO Assay Design
Disaggregation Of Revenue [Line Items]
Beginning Balance	66,216	50,000
Deferral of revenue	566,733	972,267
Recognition of deferred revenue	(632,949)	(956,051)
Ending Balance		66,216
Sample Processing
Disaggregation Of Revenue [Line Items]
Beginning Balance	438,090	244,400
Deferral of revenue	124,404	529,913
Recognition of deferred revenue	(186,888)	(336,223)
Transfer to refund liability	(281,722)
Ending Balance	$ 93,884	$ 438,090

Other Agreements - Additional I

Other Agreements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Other Agreements [Line Items]
Asset purchase agreement aggregate cash compensation paid	$ 15,000,000
Accretion expense	$ (12,936)	$ (13,821)
Measurement Input, Default Rate
Other Agreements [Line Items]
Discount rate used to calculate asset purchase obligation	2.5
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid	6.00%
Asset purchase agreement yearly fixed fees paid	$ 400,000	400,000
Accrued revenue-based payments	$ 200,000	900,000
Percentage of compounded annual interest on unpaid Obligation	2.50%
Additional revenue based payments payable	$ 54,777
NuvoGen
Other Agreements [Line Items]
Unamortized interest accretion	(79,376)	(92,311)
Accretion expense	$ (12,935)	$ (13,821)

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Minimum Principal Payments Due (Details) - NuvoGen Asset Purchase Agreement	Dec. 31, 2020USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2021	$ 512,729
2022	400,000
2023	400,000
2024	400,000
2025	400,000
2025 and beyond	2,800,021
Total NuvoGen obligation payments	4,912,750
Plus interest accretion	79,376
Total NuvoGen obligation, net	$ 4,992,126

Leases - Additional Information

Leases - Additional Information (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Lessee Lease Description [Line Items]
Lease expiration year	2023
Operating lease, description	The Company’s most significant active leases as of December 31, 2020 are for office and manufacturing space in Tucson, Arizona and a development laboratory space in San Carlos, California.
Financing lease liabilities, net of discount	$ 70,674
Financing lease liabilities, current	$ 22,563
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities
Financing lease liabilities, non current	$ 48,111
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other non-current liabilities
Financing leases, right-of-use assets	$ 66,770
Tucson, Arizona
Lessee Lease Description [Line Items]
Extended lease term	The Company amended its Tucson facility leases in December 2020 to extend the terms for one year, through January 31, 2022. The lease extension, treated as a lease modification for accounting purposes, allows for an additional extension of three years upon the same terms and conditions

Leases - Summary of Components

Leases - Summary of Components of Lease Cost for Operating Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease cost	$ 752,413	$ 618,463
Variable lease cost	125,792	131,387
Operating lease expense	878,205	749,850
Short-term lease rent expense		1,497
Total rent expense	$ 878,205	$ 751,347

Leases - Summary of Other Infor

Leases - Summary of Other Information Related to Operating Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Cash paid for amounts included in measurement of operating lease liabilities	$ 883,252	$ 770,658
Establishment of operating lease liabilities arising from obtaining right-of-use assets	$ 515,409	$ 2,038,193
Weighted-average remaining lease term – operating leases	1 year 8 months 12 days	2 years 3 months 18 days
Weighted-average discount rate – operating leases	8.00%	9.60%

Leases - Summary of Remaining M

Leases - Summary of Remaining Maturities of Operating Leases, Excluding Short-term Leases (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2021	$ 746,724
2022	319,678
2023	70,848
Total	1,137,250
Less present value discount	(83,348)
Total operating lease liabilities	1,053,902
Less operating lease liabilities - current	(685,220)	$ (758,932)
Operating lease liabilities - non-current	$ 368,682	$ 636,340

Leases - Summary of Component_2

Leases - Summary of Components of Lease Cost for Financing Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Amortization of right-of-use assets	$ 42,826	$ 46,255
Interest on lease liability	8,938	6,859
Total financing lease cost	$ 51,764	$ 53,114

Leases - Summary of Other Inf_2

Leases - Summary of Other Information Related to Financing Leases (Details)	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Weighted-average remaining lease term – financing leases	3 years 4 months 24 days	3 years 8 months 12 days
Weighted-average discount rate – financing leases	9.77%	9.77%

Leases - Summary of Remaining_2

Leases - Summary of Remaining Maturities of Financing Leases (Details)	Dec. 31, 2020USD ($)
Leases [Abstract]
2021	$ 28,355
2022	20,716
2023	18,396
2024	16,080
Total	83,547
Less present value discount	(12,873)
Financing lease liabilities, net	$ 70,674

Net Loss per Share - Additional

Net Loss per Share - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2020	Jun. 24, 2020	Sep. 30, 2019
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 11.6565
Proceeds from exercise of pre-funded warrants		$ 31,768
Warrant to purchase common stock		42,894
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants			42,894
Exercise price of warrants		$ 11.6565	$ 11.6565
Warrant expire date		Jun. 24, 2030
SVB Term Loan | Minimum
Class Of Warrant Or Right [Line Items]
Warrant to purchase common stock		42,894
Pre Funded Warrants
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 0.15
Warrant to purchase common stock		148,995
Private Placement | Institutional Accredited Investors
Class Of Warrant Or Right [Line Items]
Exercise price of warrants				$ 9.75
Private Placement | Institutional Accredited Investors | Pre Funded Warrants
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants				360,779
Exercise price of warrants				$ 9.60
Exercise price of warrants, exercisable subject to beneficial ownership limitations				$ 0.15
Warrants exercised	211,784
Proceeds from exercise of pre-funded warrants	$ 31,768
Warrant to purchase common stock		148,995

Net Loss per Share - Reconcilia

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Numerator:
Net loss	$ (20,870,218)	$ (19,297,664)
Denominator:
Weighted-average shares outstanding-basic and diluted	4,627,918	2,539,979
Net loss per share, basic and diluted	$ (4.51)	$ (7.60)

Net Loss per Share - Common Sto

Net Loss per Share - Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	487,227	193,660
Restricted Stock Units R S U
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	12,214	14,916
Warrants | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	58,689	15,794
Series A Preferred
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	158,545
QNAH convertible note
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share		53,357

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2020	Jun. 24, 2020	Sep. 30, 2019
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 11.6565
Proceeds from exercise of pre-funded warrants		$ 31,768
Warrant to purchase common stock		42,894
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants			42,894
Exercise price of warrants		$ 11.6565	$ 11.6565
Warrant expire date		Jun. 24, 2030
SVB Term Loan | Minimum
Class Of Warrant Or Right [Line Items]
Warrant to purchase common stock		42,894
Pre Funded Warrants
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 0.15
Warrant to purchase common stock		148,995
Private Placement | Institutional Accredited Investors
Class Of Warrant Or Right [Line Items]
Exercise price of warrants				$ 9.75
Private Placement | Institutional Accredited Investors | Pre Funded Warrants
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants				360,779
Exercise price of warrants				$ 9.60
Exercise price of warrants, exercisable subject to beneficial ownership limitations				$ 0.15
Warrants exercised	211,784
Proceeds from exercise of pre-funded warrants	$ 31,768
Warrant to purchase common stock		148,995

Warrants -Summary of Outstandin

Warrants -Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2020$ / sharesshares
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2020-06
Shares of Common Stock Underlying Warrants | shares	42,894
Exercise Price/Share | $ / shares	$ 11.6565
Expiration Date	2030
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-12
Shares of Common Stock Underlying Warrants | shares	9,651
Exercise Price/Share | $ / shares	$ 210
Expiration Date	2022
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2016-03
Shares of Common Stock Underlying Warrants | shares	3,021
Exercise Price/Share | $ / shares	$ 41.40
Expiration Date	2026
Common Stock Tranche one
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2018-03
Shares of Common Stock Underlying Warrants | shares	1,208
Exercise Price/Share | $ / shares	$ 115.95
Expiration Date	2028
Pre Funded Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2019-09
Shares of Common Stock Underlying Warrants | shares	148,995
Exercise Price/Share | $ / shares	$ 0.15
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-08
Shares of Common Stock Underlying Warrants | shares	1,914
Exercise Price/Share | $ / shares	$ 352.65
Expiration Date	2024

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Details)

Jan. 01, 2021shares

Nov. 20, 2020$ / sharesshares

Mar. 24, 2020USD ($)$ / sharesshares

Feb. 25, 2020USD ($)$ / sharesshares

Jan. 01, 2020shares

Nov. 30, 2019USD ($)$ / shares

Nov. 30, 2020

Mar. 31, 2020USD ($)shares

Sep. 30, 2019USD ($)$ / sharesshares

Mar. 15, 2021USD ($)shares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2015shares

Aug. 31, 2020shares

May 31, 2019shares

Dec. 31, 2018shares

Class Of Stock [Line Items]

Exercise Price/Share | $ / shares

$ 11.6565

Common stock, shares outstanding

5,199,997

3,872,682

Common stock, shares issued

5,199,997

3,872,682

Reverse stock split, description

On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen (15) shares of issued and outstanding common stock were exchanged for one share of its common stock.

Stock split conversion ratio

0.067

Common stock split Price per share | $ / shares

$ 4.27

Fractional shares from reverse stock split share

0

Common stock, shares authorized

26,666,667

26,666,667

Common stock, par value | $ / shares

$ 0.001

$ 0.001

Preferred stock, shares authorized

10,000,000

Preferred stock, par value | $ / shares

$ 0.001

Weighted-average fair value of stock options granted | $ / shares

$ 6.40

$ 14.55

Maximum aggregate number of common stock available purchase under employee stock purchase plan

16,666

Maximum number of shares that may be purchased by eligible participants under employee stock purchase plan

500

Stock issued under employee stock purchase plans

0

500

Stock issued under stock purchase plans, shares

0

500

Employee Stock Option

Class Of Stock [Line Items]

Stock option granted

387,178

84,667

Unrecognized compensation expense | $

$ 2,300,000

Compensation expense period expected to be recognized

2 years 3 months 14 days

Options to purchase common stock outstanding

487,227

193,660

136,482

Restricted Stock Units R S U

Class Of Stock [Line Items]

Unrecognized compensation expense | $

$ 300,000

Compensation expense period expected to be recognized

1 year 8 months 8 days

Weighted-average fair value of RSUs granted | $ / shares

$ 7.83

$ 28.95

Vested and unissued RSU awards, description

Vested and unissued awards at December 31, 2020 represents RSU awards granted in August 2018, January 2019, September 2019 and August 2020 for which a portion of the awards vested on December 31, 2020, but for which issuance of shares occurred in January 2021.

Vested and unissued RSU awards granted date

Aug. 31, 2018

Vested and unissued RSU awards vesting date

Dec. 31, 2020

Vested and unissued RSU awards issuance date

Jan. 31, 2021

Restricted Stock Units R S U | Share-based Payment Arrangement, Tranche One

Class Of Stock [Line Items]

Vested and unissued RSU awards granted date

Jan. 31, 2019

Restricted Stock Units R S U | Share-based Payment Arrangement, Tranche Two

Class Of Stock [Line Items]

Vested and unissued RSU awards granted date

Sep. 30, 2019

2014 Equity Incentive Plan

Class Of Stock [Line Items]

Number of shares available for issuance

0

0

Number of additional shares registered for issuance

154,907

Shares reserved for issuance

68,552

13,333

Options granted in term

10 years

2020 Equity Incentive Plan

Class Of Stock [Line Items]

Number of shares available for issuance

513,619

Shares reserved for issuance

744,685

Inducement Awards | Employee Stock Option

Class Of Stock [Line Items]

Stock option granted

0

5,333

Common Stock

Class Of Stock [Line Items]

Number of shares issued upon the conversion

183,333

Reverse stock split, description

In November 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen shares of issued and outstanding common stock were exchanged for one share of common stock.

Stock split conversion ratio

0.15

Stock issued under employee stock purchase plans

6,286

5,830

Stock issued under stock purchase plans, shares

6,286

5,830

Maximum | 2014 Equity Incentive Plan | Board Of Directors

Class Of Stock [Line Items]

Options exercise period

4 years

Minimum | 2014 Equity Incentive Plan | Board Of Directors

Class Of Stock [Line Items]

Options exercise period

1 year

Cantor Sales Agreement

Class Of Stock [Line Items]

Issuance of common stock, shares

0

Common stock price per share | $ / shares

$ 0.001

Deferred offering costs | $

$ 81,000

Reduction of commissions earned on sold shares | $

45,000

Cantor Sales Agreement | Maximum

Class Of Stock [Line Items]

Common stock aggregate offering price | $

$ 20,000,000

Percentage of commission aggregate gross proceeds from each sale of shares

3.00%

Exchange Agreement

Class Of Stock [Line Items]

Common stock, shares outstanding

274,000

Conversion of convertible preferred stock into common stock

6.67

Exchange Agreement | Series A Convertible Preferred Stock

Class Of Stock [Line Items]

Issuance of common stock, shares

10,170

Preferred stock, shares issued

41,100

Preferred stock, par value | $ / shares

$ 0.001

Issuance of common stock | $

$ 600,000

Stock issued, price per share | $ / shares

$ 59

Preferred stock, shares converted

183,333

Preferred stock, shares outstanding

23,770

Exchange Agreement | Common Stock

Class Of Stock [Line Items]

Number of shares issued upon the conversion

27,500

Pre Funded Warrants

Class Of Stock [Line Items]

Exercise Price/Share | $ / shares

$ 0.15

Lincoln Park | LP Purchase Agreement

Class Of Stock [Line Items]

Common stock price per share | $ / shares

$ 5.2155

Net proceeds from issuance of common stock from the ATM Offering | $

$ 1,000,000

Common stock value right to sell, maximum | $

$ 20,000,000

Agreement term

36 months

Minimum purchase amount extent to sell shares | $

$ 150,000

Maximum amount of any single business day’s purchase shares

166,666

Percentage of common stock outstanding

19.99%

Percentage of beneficially owing common stock

9.99%

Common stock, shares issued

41,026

197,632

Common stock weighted average price per share | $ / shares

$ 4.94

Lincoln Park | LP Purchase Agreement | Maximum

Class Of Stock [Line Items]

Number of common stock may sell in regular purchase on single business day

20,000

Lincoln Park | LP Purchase Agreement | Maximum | Closing Price of Common Stock is Not Below $7.50

Class Of Stock [Line Items]

Increased number of common stock may sell in regular purchase on single business day

23,333

Lincoln Park | LP Purchase Agreement | Maximum | Closing Price of Common Stock is Not Below $11.25

Class Of Stock [Line Items]

Increased number of common stock may sell in regular purchase on single business day

26,666

Lincoln Park | LP Purchase Agreement | Minimum

Class Of Stock [Line Items]

Closing stock price | $ / shares

$ 1.50

Lincoln Park | LP Purchase Agreement | Minimum | Closing Price of Common Stock is Not Below $7.50

Class Of Stock [Line Items]

Closing stock price of common stock | $ / shares

7.50

Lincoln Park | LP Purchase Agreement | Minimum | Closing Price of Common Stock is Not Below $11.25

Class Of Stock [Line Items]

Closing stock price of common stock | $ / shares

$ 11.25

Underwritten Public Offering

Class Of Stock [Line Items]

Issuance of common stock, shares

1,953,236

Common stock price per share | $ / shares

$ 9.75

Net proceeds from initial public offering after underwriters' discounts, commissions and offering expenses | $

$ 17,700,000

Over-Allotment Option

Class Of Stock [Line Items]

Issuance of common stock, shares

254,770

Common stock price per share | $ / shares

$ 9.165

Private Placement | Institutional Accredited Investors

Class Of Stock [Line Items]

Exercise Price/Share | $ / shares

$ 9.75

Private Placement | Institutional Accredited Investors | Pre Funded Warrants

Class Of Stock [Line Items]

Number of securities called by warrants

360,779

Exercise Price/Share | $ / shares

$ 9.60

Exercise price of warrants, exercisable subject to beneficial ownership limitations | $ / shares

$ 0.15

Warrant to purchase common stock, shares

360,779

Private Placement | Cantor Fitzgerald & Co. | Pre Funded Warrants

Class Of Stock [Line Items]

Number of securities called by warrants

211,784

Agent cash fee, percentage of gross proceeds from sale of warrants

6.00%

Net proceeds from sale of warrants | $

$ 31,768

$ 3,100,000

Warrant to purchase common stock, shares

211,784

ATM Offering

Class Of Stock [Line Items]

Gross proceeds from issuance of common stock | $

$ 7,900,000

Payment of sales commissions | $

$ 200,000

Net proceeds from issuance of common stock from the ATM Offering | $

7,500,000

Issuance of common stock | $

$ 7,545,838

ATM Offering | Subsequent Event

Class Of Stock [Line Items]

Gross proceeds from issuance of common stock | $

$ 6,900,000

Net proceeds from issuance of common stock from the ATM Offering | $

$ 6,700,000

ATM Offering | Common Stock

Class Of Stock [Line Items]

Issuance of common stock, shares

955,240

Deferred offering costs | $

100,000

Issuance of common stock | $

$ 955

ATM Offering | Common Stock | Subsequent Event

Class Of Stock [Line Items]

Issuance of common stock, shares

1,000,000

Employee Stock Purchase Plan

Class Of Stock [Line Items]

Net proceeds from issuance of common stock from the ATM Offering | $

$ 17,250

Number of shares available for issuance

11,658

Shares reserved for issuance

24,922

Vested and unissued RSU awards, description

The number of shares of common stock reserved for issuance automatically increases on January 1 of each calendar year, from January 1, 2016 to January 1, 2024 by the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 13,000 shares, or (iii) a number determined by the Company’s Board of Directors that is less than (i) and (ii).

Common stock issuance offering date

Jan. 1, 2016

Common stock issuance expiration date

Jan. 1, 2024

Percentage of common stock outstanding

1.00%

Options to purchase common stock outstanding

13,000

Maximum contribution eligible compensation during a period to purchase common stock

15.00%

Fair market value of company common stock, shares offering price

85.00%

Fair market value of company common stock, shares purchase price

85.00%

Employee Stock Purchase Plan | Subsequent Event

Class Of Stock [Line Items]

Number of additional shares registered for issuance

13,000

Stockholders Equity - Summary o

Stockholders Equity - Summary of Stock Based Compensation Recognized in Consolidated Statement of Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 1,584,785	$ 1,156,567
2014 Employee Stock Purchase Plan
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	21,186	66,238
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	1,461,190	859,653
Selling, General and Administrative | 2014 Employee Stock Purchase Plan
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	12,106	43,615
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	106,267	243,804
Research and Development | 2014 Employee Stock Purchase Plan
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	5,248	18,454
Cost of Product and Product-related Services Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	17,328	53,110
Cost of Product and Product-related Services Revenue | 2014 Employee Stock Purchase Plan
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 3,832	$ 4,169

Stockholders Equity - Summary_2

Stockholders Equity - Summary of Stock Option Plans Activity (Details) - Employee Stock Option - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	193,660	136,482
Number of Shares, Granted	387,178	84,667
Number of Shares, Exercised		(3,617)
Number of Shares, Forfeited	(67,369)	(10,771)
Number of Shares, Expired/Cancelled	(26,242)	(13,101)
Number of Shares, Ending Balance	487,227	193,660	136,482
Number of Shares, Exercisable	187,031	92,058
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 35.55	$ 46.05
Weighted-Average Exercise Price Per Share, Granted	7.81	22.20
Weighted-Average Exercise Price Per Share, Exercised		33.45
Weighted-Average Exercise Price Per Share, Forfeited	12.99	49.35
Weighted-Average Exercise Price Per Share, Expired/Cancelled	32.04	48.45
Weighted-Average Exercise Price Per Share, Ending Balance	16.78	35.55	$ 46.05
Weighted-Average Exercise Price Per Share, Exercisable	$ 27.07	$ 42.60
Weighted-Average Remaining Contractual Life, Outstanding	8 years 7 months 6 days	8 years	7 years 6 months 6 days
Weighted-Average Remaining Contractual Life, Exercisable	7 years 6 months	6 years 7 months 6 days
Aggregate Intrinsic Value, Balance	$ 1,536	$ 781	$ 366,007
Aggregate Intrinsic Value, Exercised		21,380
Aggregate Intrinsic Value, Exercisable	$ 305	$ 1,440

Stockholders Equity - Summary_3

Stockholders Equity - Summary of Material Factors Incorporated in Black-Scholes Model in Estimating Fair Value of Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.34%	1.43%
Risk-free interest rate, maximum	1.65%	2.21%
Expected volatility, minimum	109.10%	63.90%
Expected volatility, maximum	149.90%	97.10%
Expected dividend yield	0.00%	0.00%
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.18%	1.88%
Risk-free interest rate, maximum	1.58%	2.37%
Expected volatility, minimum	65.80%	79.50%
Expected volatility, maximum	88.90%	85.80%
Expected term	6 months	6 months
Expected dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 4 months 24 days	5 years 6 months
Minimum | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock on grant date	$ 4.35	$ 10.20
Minimum | Common Stock | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock on grant date	$ 8.70	$ 27.75
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 10 months 24 days	6 years 1 month 6 days
Maximum | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock on grant date	$ 11.25	$ 33.90
Maximum | Common Stock | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock on grant date	$ 9.75	$ 60

Stockholders Equity - Summary_4

Stockholders Equity - Summary of Material Factors Incorporated in Black-Scholes Model in Estimating Fair Value of Options Granted (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Class Of Stock [Line Items]
Expected dividend assumed value	$ 0
2014 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Expected dividend assumed value	$ 0

Stockholders Equity - Summary_5

Stockholders Equity - Summary of RSU Award Activity (Details) - Restricted Stock Units R S U - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Restricted Stock Units (RSU)
Beginning Balance	14,916	15,180
Granted	7,000	5,167
Released	(7,911)	(5,431)
Forfeited	(1,791)
Ending Balance	12,214	14,916
Vested and unissued at December 31, 2020	1,390
Weighted Average Grant Date Fair Value Per Share
Beginning Balance	$ 43.65	$ 49.50
Granted	7.83	28.95
Released	35.85	49.65
Forfeited	41.23
Ending Balance	28.61	$ 43.65
Vested and unissued at December 31, 2020	$ 33.21

Stockholders Equity - Summary_6

Stockholders Equity - Summary of Shares Purchased under ESPP'S Six Month Purchase Periods (Details) - $ / shares	6 Months Ended
	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019
Class Of Stock [Line Items]
Number of Shares	3,253	3,033	2,664	2,666
2014 Employee Stock Purchase Plan Group A
Class Of Stock [Line Items]
Number of Shares	2,857	3,033	1,830	1,972
Price per Share	$ 4.87	$ 8.29	$ 8.55	$ 23.59
2014 Employee Stock Purchase Plan Group B
Class Of Stock [Line Items]
Number of Shares	396		349	389
Price per Share	$ 4.87		$ 8.55	$ 26.78
2014 Employee Stock Purchase Plan Group C
Class Of Stock [Line Items]
Number of Shares			320	305
Price per Share			$ 8.55	$ 26.78
2014 Employee Stock Purchase Plan Group D
Class Of Stock [Line Items]
Number of Shares			165
Price per Share			$ 8.55

Commitments and Contingencies -

Commitments and Contingencies - Schedule Of Product Warranty Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 94,482	$ 63,461
Cost of warranty claims	(32,866)	(40,055)
Increase in warranty reserve	31,080	71,076
Ending balance	$ 92,696	$ 94,482

Commitments and Contingencies_2

Commitments and Contingencies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Discretionary contributions company may make	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Line Items]
Income tax examination, likelihood of unfavorable settlement	greater than 50 percent
Uncertain tax positions	$ 3,000,000	$ 2,700,000
Accrued interest or penalties	0	0
Recognized interest or penalties	0	0
Valuation allowance	$ 48,626,925	43,350,682
Change in valuation reserve		5,300,000
Period for cumulative change in ownership	3 years
Gross unrecognized tax benefits	$ 2,960,842	$ 2,731,015	$ 1,538,220
Unrecognized tax benefits if recognized would impact effective tax rate	$ 0
CARES Act of 2020 percentage of NOL carryovers and carrybacks offsetting taxable income	100.00%
Research and Experimental Tax Credits
Income Tax Disclosure [Line Items]
Gross unrecognized tax benefits	$ 3,000,000
Minimum
Income Tax Disclosure [Line Items]
Cumulative changes in ownership percentage	50.00%
Federal
Income Tax Disclosure [Line Items]
NOL carryforwards	$ 177,600,000
State
Income Tax Disclosure [Line Items]
NOL carryforwards	124,500,000
With Expiration | Federal
Income Tax Disclosure [Line Items]
NOL carryforwards	$ 121,800,000
Beginning Expiration Year | Federal
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2021
Tax credit carryforward, expiration year	2021
Beginning Expiration Year | State
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2027
Tax credit carryforward, expiration year	2021
Ending Expiration Year | Federal
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2037
Ending Expiration Year | State
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2040

Income Taxes - Summary of Loss

Income Taxes - Summary of Loss Before Income taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
U.S. pre-tax loss	$ (20,855,184)	$ (19,332,809)
Foreign pre-tax gain (loss)	(619)	38,524
Net loss before income taxes	$ (20,855,803)	$ (19,294,285)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Current:
State	$ 10,860	$ 3,379
Foreign	3,555
Total current income tax expense	14,415	3,379
Total income tax expense	$ 14,415	$ 3,379

Income Taxes - Difference in Ac

Income Taxes - Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Line Items]
Computed tax (benefit) at 21%	$ (4,379,719)	$ (4,051,800)
State taxes, net of federal benefit	(832,055)	(881,670)
Stock-based compensation	310,811	183,167
Foreign tax rate differential	3,685	4,298
Return to provision	26,120	80,668
Other	31,850	51,737
Uncertain tax position adjustment for prior periods	(5,694)	650,687
Increase in valuation allowance	5,276,244	4,610,490
Total income tax expense	14,415	3,379
State
Income Tax Disclosure [Line Items]
Research and development tax credit	(218,991)	(342,320)
Federal
Income Tax Disclosure [Line Items]
Research and development tax credit	$ (197,836)	$ (301,878)

Income Taxes - Difference in _2

Income Taxes - Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	21.00%	21.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 43,308,483	$ 38,357,970
Research and development credits	3,475,341	3,061,981
Deferred revenue	50,429	154,497
Inventory reserve	6,653	10,155
Fixed assets and intangibles	313,117	217,332
Lease liability	269,147	359,603
Other	211,574	150,134
Gross deferred tax assets	48,909,640	43,768,107
Valuation allowance	(48,626,925)	(43,350,682)
Deferred tax assets, net	282,715	417,425
Deferred tax liabilities:
Right of use asset	257,705	311,633
Other	25,010	105,792
Total deferred tax liabilities	282,715	417,425
NuvoGen
Deferred tax assets:
Accrued liability	$ 1,274,896	$ 1,456,435

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 2,731,015	$ 1,538,220
Increases to prior positions		650,687
Decreases to prior positions	(5,694)
Increases for current year positions	235,521	542,108
Balance at end of year	$ 2,960,842	$ 2,731,015

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - ATM Offering - USD ($) $ in Millions	2 Months Ended	12 Months Ended
	Mar. 15, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Gross proceeds from issuance of common stock		$ 7.9
Net proceeds from issuance of common stock from the ATM Offering		$ 7.5
Common Stock
Subsequent Event [Line Items]
Issuance of common stock, shares		955,240
Subsequent Event
Subsequent Event [Line Items]
Gross proceeds from issuance of common stock	$ 6.9
Net proceeds from issuance of common stock from the ATM Offering	$ 6.7
Subsequent Event | Common Stock
Subsequent Event [Line Items]
Issuance of common stock, shares	1,000,000